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Clinical and neuropathological studies have shown that tau pathology better correlates with the severity of dementia than amyloid
plaque burden, making tau an attractive target for the cure of Alzheimer’s disease. We have explored whether passive immuniza-
tion with the 12A12 monoclonal antibody (26–36aa of tau protein) could improve the Alzheimer’s disease phenotype of two well-
established mouse models, Tg2576 and 3xTg mice. 12A12 is a cleavage-specific monoclonal antibody which selectively binds the
pathologically relevant neurotoxic NH226-230 fragment (i.e. NH2htau) of tau protein without cross-reacting with its full-length
physiological form(s). We found out that intravenous administration of 12A12 monoclonal antibody into symptomatic (6 months
old) animals: (i) reaches the hippocampus in its biologically active (antigen-binding competent) form and successfully neutralizes its
target; (ii) reduces both pathological tau and amyloid precursor protein/amyloidb metabolisms involved in early disease-associated
synaptic deterioration; (iii) improves episodic-like type of learning/memory skills in hippocampal-based novel object recognition
and object place recognition behavioural tasks; (iv) restores the specific up-regulation of the activity-regulated cytoskeleton-associ-
ated protein involved in consolidation of experience-dependent synaptic plasticity; (v) relieves the loss of dendritic spine connectiv-
ity in pyramidal hippocampal CA1 neurons; (vi) rescues the Alzheimer’s disease-related electrophysiological deficits in hippocampal
long-term potentiation at the CA3-CA1 synapses; and (vii) mitigates the neuroinflammatory response (reactive gliosis). These find-
ings indicate that the 20–22 kDa NH2-terminal tau fragment is crucial target for Alzheimer’s disease therapy and prospect im-
munotherapy with 12A12 monoclonal antibody as safe (normal tau-preserving), beneficial approach in contrasting the early
Amyloidb-dependent and independent neuropathological and cognitive alterations in affected subjects.
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Introduction
Recent in vitro and in vivo data have highlighted a cru-
cial role of proteolytic fragments of tau protein, in par-
ticular those derived from truncation at its N-terminal
domain, in the initiation/progression of Alzheimer’s dis-
ease and other related tauopathies, thus paving the way
for their potential use as therapeutic targets or as bio-
markers for diagnosing dementia and/or monitoring dis-
ease progression (Avila et al., 2016a; Quinn et al., 2018;
Sebastián-Serrano et al., 2018). On the one hand, tau
cleavage may generate amyloidogenic fragments that initi-
ate its aggregation which, in turn, can cause toxicity
(Wang et al., 2010). On the other hand, tau proteolysis
may result in production of noxious, both intracellular
and extracellular, truncated species which drive neurode-
generation independently of aggregative pathway(s) and
in a fragment-dependent manner as a result of their dele-
terious action on pre- and/or post-synaptic functions and/
or their secretion and transcellular propagation (Quinn
et al., 2018).
Extracellular cleaved tau is toxic to neurons by increas-
ing the Ab production (Bright et al., 2015) and/or by
impairing synaptic plasticity (Fà et al., 2016; Florenzano
et al., 2017; Borreca et al., 2018; Hu et al., 2018).
Hyperphosphorylation and caspase-3 cleavage of tau
(Asp421), which promote aggregation, also favour the
protein secretion in vitro (Plouffe et al., 2012). The
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amino-terminal projection domain of human tau—which
interacts with the plasma membrane (Brandt et al., 1995)
and undergoes early conformational changes in human
tauopathies including Alzheimer’s disease (Combs et al.,
2016, 2017)—is endowed with deleterious action(s),
mainly at nerve endings (King et al., 2006; Ittner et al.,
2010; Amadoro et al., 2012; Zhou et al., 2017). The N-
terminus extremity of tau, despite the lack of the micro-
tubule binding domains which abnormally aggregate to
form paired helical filaments, is prone to come into
higher order of oligomerization (Feinstein et al., 2016)
and is specifically released into the extracellular space in
an in situ tauopathy model (Kim et al., 2010), suggesting
a potential role for molecular ‘templating’ in the propaga-
tion of neurofibrillary lesions. Soluble C-terminally trun-
cated tau species are also preferentially secreted from
synaptosomes of Alzheimer’s disease brains (Sokolow
et al., 2015) and in conditioned media from patient-
derived induced pluripotent stem cell cortical neurons
(Bright et al., 2015; Kanmert et al., 2015; Sato et al.,
2018). Interestingly, although full-length tau is found in
CSF from healthy humans, a heterogeneous population of
fragments—including the NH2-terminal and/or prolin-rich
domain—is mainly discernible in Alzheimer’s disease
patients (Johnson et al., 1997; Portelius et al., 2008;
Meredith et al., 2013; Amadoro et al., 2014; Chen et al.,
2019; Cicognola et al., 2019). Exosomes-associated NH2-
derived tau fragments are also detected in CSF from
Alzheimer’s disease patients (Saman et al., 2012) and a
different CSF pattern of NH2-derived tau fragments
may reflect disease-specific neurodegenerative processes
(Borroni et al., 2009). Consistently, passive immunother-
apy with antibody targeting the N-terminal projection do-
main of full-length human tau has shown to be beneficial
in Alzheimer’s disease transgenic (Tg) mice by improving
the cognitive deficits (Yanamandra et al., 2013; Dai
et al., 2015; Subramanian et al., 2017) and blocking the
seeding/spreading of tau pathology (Dai et al., 2018).
Both intracerebroventricular infusion and peripheral ad-
ministration of anti-tau antibodies specific for N-terminal
25–30 epitopes are curative in P301S mice model of tau-
opathy, by preventing the brain atrophy and ameliorating
the motor/sensorimotor functions (Yanamandra et al.,
2013, 2015). Immunization with antibody directed
against the N-terminal end of full-length tau protein (Dai
et al., 2017) significantly reduced the level of amyloid
precursor protein (APP), amyloid-b peptides (Ab40) and
Ab42 in CA1 region of Alzheimer’s disease animal mod-
els, indicating that tau-based immunotherapy is actually
able to restore the Ab-dependent and/or independent syn-
aptic dysfunction(s) which occur at early stages in
Alzheimer’s disease and other related dementias (Pedersen
and Sigurdsson, 2015; Panza et al., 2016). However, al-
beit tau appears to be the main factor underlying the de-
velopment and progression of Alzheimer’s disease
(Kametani and Hasegawa et al., 2018; Castellani and
Perry, 2019), its expression at physiological level is
required for neuronal functions underlying learning and
memory (Pooler et al., 2014; Regan et al., 2017) and its
down-regulation, even if moderate, has been proved to
have deleterious effects, both in vitro and in vivo (Biundo
et al., 2018; Velazquez et al., 2018). As a consequence,
the development of selectively targeting antibodies against
pathogenic tau may have a unique therapeutic advantage
by leading to valuable, beneficial effects—in the absence
of unwanted consequences due to the ‘loss of function’ of
normal protein—in the cure of human, chronic neurode-
generative tauopathies which are sometimes expected to
require long-term treatments with multiple and high-dose
administrations of drugs (Kontsekova et al., 2014;
Elmaleh et al., 2019).
In this framework, we developed a neo-epitope anti-
body directed against the N-terminal sequence of human
tau protein DRKD(25)-QGGYTMHQDQE (Amadoro
et al., 2012) which encompasses a conserved cleavage-site
sequence previously identified in cellular and animal
Alzheimer’s disease models (Corsetti et al., 2008) and in
human Alzheimer’s disease brains (Rohn et al., 2002).
12A12 (formerly Caspase-Cleaved protein-NH24268 tau
antiserum, Amadoro et al., 2012) is a monoclonal anti-
body (mAb) which recognizes the newly created
D-25NH2tau(Q26–36aa)-terminus of degradation prod-
uct(s) of tau without cross-reacting with the same amino
acidic stretch from full-length isoforms of intact, normal
protein (Amadoro et al., 2019; Supplementary Fig. 1).
The pathologically relevant NH2tau 26–44aa stretch,
which is the minimal active moiety of a neurotoxic 20–
22 kDa NH2-derived tau peptide (aka NH2htau), accu-
mulates at Alzheimer’s disease pre-synaptic terminals
(Amadoro et al., 2006, 2010, 2012; Corsetti et al., 2015)
and is present in CSFs from living patients suffering from
Alzheimer’s disease and other non-Alzheimer’s disease
neurodegenerative diseases (Amadoro et al., 2014).
Interestingly, this peptide is able to negatively impact on
normal synaptic function(s) in vitro (Florenzano et al.,
2017) and in vivo (Borreca et al., 2018), suggesting that
its antibody-mediated selective clearance can have import-
ant clinical and translational implications in contrasting
the earliest neuropathological and cognitive alterations
associated with human tauopathies, including Alzheimer’s
disease (Bright et al., 2015; Sokolow et al., 2015;
Barthélemy et al., 2016a, b; Sato et al., 2018; Cicognola
et al., 2019).
In this study, we explored the potentially beneficial
immunotherapeutic power of the 12A12mAb by means
of its intravenous (i.v.) administration in two lines of
Alzheimer’s disease Tg animals with different genetic
backgrounds, such as Tg2576 carrying the APP KM670/
671NL Swedish mutation and 3xTg mice expressing the
amyloid precursor protein KM670/671NL Swedish muta-
tion, tauP301L, PS1M146V human transgenes.
Relevantly, unlike other murine or humanized NH2tau-
directed immunotherapeutic antibodies (Yanamandra
et al., 2013, 2015; Dai et al., 2015, 2017, 2018;
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Subramanian et al., 2017; Qureshi et al., 2018),
12A12mAb reacts with the 20–22 kDa neurotoxic NH2-
truncated tau but not with the physiological full-length
form of protein (Corsetti et al., 2008; Amadoro et al.,
2012) advocating its in vivo use as safe, more harmless




All experiments involving animals were performed in ac-
cordance with the ARRIVE guidelines and were carried
out in accordance with the ethical guidelines of the
European Council Directive (2010/63/EU); experimental
approval was obtained from the Italian Ministry of Health
(protocol # 524/2017 PR; 554/2016-PR). Only male sub-
jects were used to avoid changes in female hormone state
that can affect cognitive data. All efforts were made to
minimize the number of animals used and suffering.
One, 3- and 6-month-old Tg2576 and 3xTg mice (Tg-
Alzheimer’s disease) (n¼ 8–10 per group/treatment) and
age-matched wild-type (WT) controls (n¼ 8–10 per
group/treatment) were used in this study.
Heterozygous Tg2576 mice overexpressing the APP695
with the Swedish mutation (APP KM670/671NL,
TgHuAPP695swe: Tg2576) in a hybrid genetic back-
ground (87% C57BL/6 12.5% SJL) (Hsiao et al., 1996)
were subsequently backcrossed to C57BL/6xSJL F1
females and the offspring were genotyped to confirm the
presence of human mutant APP DNA sequence by PCR.
WT littermates were used as controls.
The homozygous 3xTg mice harbouring human amyl-
oid precursor protein KM670/671NL Swedish mutation
and tauP301L transgenes with knock-in PS1M146V
under the control of the mouse Thy1.2 promoter were
obtained from The Jackson Laboratory (https://www.jax.
org/strain/004807). Mice were bred on the mixed C7BL/
6; 129X1/SvJ; 129S1/Sv genetic background and geno-
types were confirmed by PCR on tail biopsies (Oddo
et al., 2003). B6129SF2/J strain mice, used as WT con-
trols in the present study, were the offspring of a cross
between C57BL/6J females (B6) and 129S1/SvImJ males
(129S); they are commonly used as controls for genetical-
ly engineered strains generated with 129-derived embry-
onic stem cells and maintained on a mixed B6; 129
background (https://www.jax.org/strain/101045). The
housing conditions (four or five animals per cage) in
pathogen-free facilities were controlled (temperature
22C, 12 h light/12 h dark cycles, humidity 50–60%)
with ad libitum access to chow and water.
Immunization scheme
The N-terminal tau 12A12 antibody (26–36aa) was pro-
duced and characterized by monoclonal antibodies core
facility at EMBL—Monterotondo, Rome, Italy (Dott.
Alan Sawyer), as previously described in Florenzano
et al. (2017). 12A12mAb was purified from hybridoma
supernatants according to standard procedures and its
purity was determined using sodium dodecyl sulphate-
polyacrylamide gel electrophoresis and Coomassie stain-
ing. In detail, the hybridoma supernatant was precipitated
by ammonium sulphate (336 g/l). After precipitation, the
solution was centrifuged at 10 000 g for 1 h and the pel-
let was dissolved in phosphate-buffered-saline (PBS) and
dialyzed against the same buffer. The solution was centri-
fuged at 10 000 g for 30 min and loaded on a HiTrap
Protein G HP (GE Healthcare) equilibrated with PBS.
The column was washed with PBS (5 column volumes).
121A12mAb was eluted with 0.1 M Glycine-HCl, pH
2.7. The fractions containing the antibody were neutral-
ized by 1 M Tris-HCl, pH 9.0, collected and immediately
dialyzed against PBS. 121A12mAb concentration was
determined by measuring the absorbance at 280 nm. The
average yield was 8 mg/l of cell supernatant. 12A12mAb
was 95% pure and contained 1 U/mg of endotoxin
(LAL Chromogenic Endotoxin quantitation kit; Thermo
Scientific).
To minimize experimental variability, all mice were ini-
tially grouped according to their body weight and age
and mice from the same litter were finally assigned to
different groups. For each animal strain (Tg2576, 3xTg),
the grouped mice were randomized into: (i) WT mice
treated with saline vehicle; (ii) WT mice treated with
12A12mAb (30 lg/dose); (iii) age-matched Tg-Alzheimer’s
disease mice treated with saline or non-specific mouse
Immunoglobulin (IgG) (normal mouse IgG, Santa Cruz
sc-2025, 30 lg/dose); and (iv) age-matched Tg-Alzheimer’s
disease mice treated with 12A12mAb (30 lg/dose) or
non-specific mouse IgG (normal mouse IgG, Santa Cruz
sc-2025, 30 lg/dose). Animals were infused over 14 days
with two weekly injections administered on two alternate
days to the lateral vein of the tail. The dose and route of
immunization were based on prior studies using
Alzheimer’s disease Tg mice (Castillo-Carranza et al.,
2015). In details, mice were placed in a restrainer
(Braintree Scientific), and an inch of the tail was shaved
and placed in warm water to dilate veins. After injection
via the lateral tail vein, mice were returned to home
cages and kept under general observation. Abnormalities
in overall health, home-cage nesting, sleeping, feeding,
grooming, body weight and condition of the fur of ani-
mals were noted.
Tissue collection, harvesting and
preparation
For biochemical analysis, tissue sampling was carried out
according to Mably et al. (2015) with some modifica-
tions. Briefly, 2 days following the last injection, animals
were sacrificed by cervical dislocation to avoid anaesthe-
sia-mediated tau phosphorylation (Planel et al., 2007)
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and intra-cardially perfused with ice-cold PBS using a
30-ml syringe to remove blood contamination. Brains
were collected, the meninges were carefully removed and
dissected hippocampi were immediately frozen on dry-ice
and, then, stored at 80C until use.
Hippocampal total protein lysates were carried out
according to Castillo-Carranza et al. (2015) with some
modifications. In details, frozen mice hippocampi were
diced and homogenized in PBS with a protease inhibitor
mixture (Roche) and 0.02% NaN3 using a 1:3 (w/v) dilu-
tion. Samples were then centrifuged at 10 000 rpm for
10 min at 4C and the supernatants were collected.
Tris-buffered saline (TBS) extracts were carried out
according to Mably et al. (2015) with some modifica-
tions. Frozen mice hippocampi were homogenized in five
volumes (wt/vol) TBS, pH 7.4, plus proteases inhibitor
cocktail (Sigma-Aldrich P8340) and phosphatase inhibitor
cocktail (Sigma-Aldrich, Oakville, Ontario, Canada
P5726/P2850) with 30 strokes of a glass Dounce tissue.
The homogenate was centrifuged at 90 000 g at 4C for
1 h. The supernatant (TBS extract) was removed and
stored at 20C.
Synaptosomes preparations were carried out as previ-
ously reported (Corsetti et al., 2015; Florenzano et al.,
2017).
Cloning, bacterial expression and
purification of the 20–22 kDa
NH226-230 tau fragment (aka
NH2htau)
cDNA fragment coding for the amino acids 26–230 of
the isoform 4 of human tau protein (htau40) was cloned
into the vector pET-11a (Novagen) suitable for the ex-
pression of recombinant proteins in BL21DE3 Gold
Escherichia coli cells. After induction with IPTG, recom-
binant protein in lysates from bacterial pellet was purified
to homogeneity by a two-step procedure: step 1 was a
HiCood Q Sepharose 16/10; step 2 was Hitrap Phenyl
5 ml. Degree of protein purification was evaluated by
Coomassie Brilliant Blue G-250 and checked by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis under
reducing conditions by western blotting with commercial
human-specific NH2-tau antibody (DC39N1 45–73aa)
and with 12A12mAb (26–36aa). The molecular identity
of purified peptide fraction was finally checked by elec-
trospray ionization mass spectrometry.
Detection of the NH2htau fragment
by 12A12mAb-based enzyme-linked
immunosorbent assay
High-binding black 96 well plates (Costar 3925, Corning,
NY) were coated overnight at 4C following the addition
of 5 lg/ml 12A12mAb capture antibody diluted in coat-
ing buffer (50 mM NaHCO3, pH9.6). Plates were washed
with PBST (PBS containing 0.05% Tween-20) and incu-
bated with 5% non-fat dry milk (w/v) in PBST at room
temperature (RT) for 2–4 h while shaking to block non-
specific binding sites. Plates were washed with PBST and
incubated (50 ll/well) overnight at 4C while shaking
with recombinant NH226-230 tau fragment standard
curves prepared in assay buffer concentration of 5% milk
(w/v) and 0.05% Tween-20 (v/v) in PBS, pH 8. Plates
were washed with PBST and incubated (50 ll/well) over-
night at 4C with rabbit H150 antibody (1–150aa;
Santa-Cruz sc-5587) diluted to the final concentration of
2.5 lg/ml in assay buffer concentration of 5% milk and
0.05% Tween-20 (v/v) in PBS. Plates were then washed
with PBST and added with 50 ll/well of rabbit horserad-
ish peroxidase-conjugated secondary antibody for 1 h at
RT. Plates were washed with PBST and developed at RT
using TMB substrate (T0440; Sigma-Aldrich, Oakville,
Ontario, Canada). Luminescence counts were measured
using Packard TopCount (PerkinElmer, MA). Log-trans-
formed luminescence counts from individual samples were
interpolated to concentration using a second-order poly-
nomial fit to the respective standards (GraphPad Prism
5.00, GraphPad Software, San Diego).
Detection of i.v.-delivered
12A12mAb in TBS brain extracts
The concentration of i.v. delivered anti-tau 12A12mAb
was measured in TBS brain extracts according to Mably
et al. (2015) with some modifications. A solid-phase en-
zyme-linked immunosorbent assay (ELISA) was performed
on the plate-immobilized synthetic NH226-44aa which
was used as catching antigenic peptide, being the minimal
Alzheimer’s disease-relevant (Borreca et al., 2018), active
moiety of the parental longer NH226-230 (Amadoro
et al., 2004, 2006). Clear 96 well high-binding plates
(Costar 3925, Corning, NY) were coated (50 ll/well) of
5 lg/ml synthetic NH226-44aa in coating buffer (0.05 M
Carbonate-Bicarbonate, pH9.6) overnight at 4C. Wells
were washed twice with PBST and loaded (50 ll/well)
with (i) the standard curve prepared by making serial
dilutions of 12A12mAb (250–0.12 ng/ml), (ii) the TBS
extracts diluted 1/50, 1/10, 1/2, 1/1.3 or (iii) blanks
diluted in assay buffer concentration of 5% milk and
0.05% Tween-20 (v/v) in PBS overnight at 4C. Plates
were then washed with PBST and added with 50 ll/well
of rabbit horseradish peroxidase-conjugated secondary
antibody for 1 h at RT. Plates were washed with PBST
and developed at RT using TMB substrate (T0440;
Sigma-Aldrich, Oakville, Ontario, Canada). Luminescence
counts were measured using Packard TopCount
(PerkinElmer, MA). Log-transformed luminescence counts
from individual samples were interpolated to concentra-
tion using a second-order polynomial fit to the respective
standards (GraphPad Prism 7.00, GraphPad Software,
San Diego).
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Cell culture, treatment and protein
lysates preparation
SH-SY5Y human neuroblastoma cells were cultured and
terminally differentiated into post-mitotic neurons accord-
ing to Corsetti et al. (2008). Culture treatment and pro-
tein lysates preparation were carried out by using
standard procedures, according to Borreca et al. (2018).
Western blot analysis and
densitometry
Western blot analysis and densitometry were carried out
by using standard procedures, according to Borreca et al.
(2018).
The following antibodies were used: anti-Ab/APP 6E10
(4–9aa) mouse MAB1560 Chemicon; anti-Alzheimer pre-
cursor protein 22C11 (66–81aa of N-terminus) mouse
APP-MAB348 Chemicon Temecula-CA; anti-pan tau pro-
tein H150 (1–150aa of N-terminus) rabbit sc-5587
Santa Cruz Biotechnology; anti-pan tau protein
DC25(microtubule binding repeat) mouse T8201 Sigma-
Aldrich; tau 21 (21–36aa of N-terminus) rabbit
AHB0371 Biosource International (USA); anti-N-tau (45–
73aa) DC39N1 mouse T8451 Sigma-Aldrich; neuronal
marker b III tubulin antibody mouse ab78078 (clone
2G10) Abcam; GAPDH antibody (6C5) mouse sc-32233
Santa Cruz Biotechnology; activity-regulated cytoskeleton-
associated protein (C-7) mouse sc-17839 Santa Cruz
Biotechnology; glial fibrillary acidic protein antibody rab-
bit Z0334 Dako; Iba1 antibody rabbit Wako 016-20001
(for WB).
Novel object recognition test
Two days after the last i.v. injection, mice run the novel
object recognition (NOR) task (Antunes and Biala, 2012)
to check the hippocampal-dependent episodic memory
(Bevins and Besheer, 2006; Akkerman et al., 2012a, b).
The entire task was performed in three consecutive ses-
sions during the same day (1-day version), according to
previously published protocol (Borreca et al., 2018).
Object place recognition test
The object place recognition paradigm involves the activ-
ity of the hippocampus and is used to test the short-term
memory (Vogel-Ciernia and Wood, 2014). The animals,
which underwent the NOR paradigm with a training and
test session, were tested in the object place recognition
paradigm 24 h later, with a separated training and test
session. The objects used for the object place recognition
were different from those used previously for the NOR
test in order to avoid possible confounding effects. The
entire behavioural task including three phases (a common
habituation phase, a training phase and a test phase) was




Evaluation of short-term working memory was carried
out by using the spontaneous alternation version of the
Y-maze, which involves different brain structures ranging
from the hippocampus to the prefrontal cortex. Y-maze
testing also indicates overall activity, or hyperactivity,
based on the number of arm entries Spontaneous alterna-
tion, expressed as a percentage, was calculated by divid-
ing the number of entries into all three arms on
consecutive choices (correct choices) by number of arm
entries subtracted by two, then multiplying the quotient
by 100 (Hiramatsu et al., 1997; Wall and Messier,
2002). A high spontaneous alternation rate is indicative
of sustained working memory because the animals must
remember which arm was entered last to know not to re-
enter it.
Energy metabolism
Energy expenditure (EE) and oxygen consumption (VO2)
were measured by an indirect calorimeter system (TSE
PhenoMaster/LabMaster SystemV
R
) in vehicle- or
12A12mAb-treated mice by a constant air flow of 0.35 l/
min. Mice were adapted for 6 h to the metabolic chamber
before the start of recording, and VO2 was measured
every 30 min in each mouse, starting at 7:00 PM and
ending automatically after 4 days (96 h later). RT was
kept constant (22 6 1C). The EE for each sample point
was evaluated across the 48 h of total recording.
Locomotor activity was assessed during the indirect cal-
orimetric assay by the number of infra-red beams broken.
Each cage of the calorimeter system is equipped with the
InfraMotV
R
device that uses ‘passive infrared sensors’ to
detect and record the motor activity of the mouse by the
body-heat image and its spatial displacement across time.
Any type of body movement was detected and recorded
as activity counts. EE was also analysed by considering
animals’ steady conditions or lack of motor activity (rest-
ing EE, REE; only values between 0 and 2 activity counts
were included).
Golgi-Cox staining and dendritic
spine analysis
Two days after the last i.v. injection, mice were sacrificed
with a lethal dose of anaesthetic (Zoletil/Rompun 800
and 100 mg/kg, respectively) and perfused transcardially
with 0.9% saline solution. Brains were dissected and im-
mediately immersed in a Golgi-Cox solution (1%
K2Cr2O7, 1% HgCl2 and 0.8% K2CrO4) at RT for
6 days, according to a previously described protocol
(Gibb and Kolb, 1998; Rosoklija et al., 2014). On the
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seventh day, brains were transferred in a 30% sucrose
solution for cryoprotection and then sectioned with a
vibratome. Staining and dendritic spine analysis was car-
ried out according to standard criteria (Horner and
Arbuthnott, 1991; Leuner et al., 2003) and by using pre-
viously published method (Borreca et al., 2018).
Statistical comparisons were made on single mouse values
obtained by averaging the number of spines counted on
neurons of the same mouse.
Electrophysiological recordings
Two days after the last i.v. injection of 12A12mAb, mice
were anaesthetized by halothane or isofluorane inhalation
and decapitated. The brain was rapidly removed and put
in ice-cold cutting solution (in mM: 124 NaCl, 3.2 KCl,
1 NaH2PO4, 26 NaHCO3, 2 MgCl2, 1 CaCl2, 10 glu-
cose, 2 sodium pyruvate and 0.6 ascorbic acid, bubbled
with 95% O2–5% CO2, pH 7.4). Electrophysiological
recordings were performed on hippocampal coronal slices
(400 lm thick) by using standard procedures (Podda
et al., 2016; Nobili et al., 2017).
Statistical analysis
In box-and-whisker plots, the centre lines denoted median
values, edges were upper and lower quartiles, whiskers
showed minimum and maximum values and points were
individual experiments. Other data were expressed as
mean 6 SEM. All data were representative of at least
three separate experiments (n ¼ independent experi-
ments). Statistically significant differences were calculated
by one-way or two-way analysis of variance (ANOVA)
followed by Bonferroni’s, Fisher’s and Dunnett’s post hoc
tests for multiple comparisons among more than two
groups. P< 0.05 was accepted as statistically significant
(*P< 0.05; **P< 0.01; ***P< 0.0005; ****P< 0.0001).
All statistical analyses were performed using GraphPad
Prism 7 software.
Data availability
The datasets used and/or analysed during the current
study and detailed protocols/experimental procedures are
available from the corresponding author on reasonable




12A12mAb is biologically active in
the animals’ hippocampus
Tg2576 and 3xTg mice—two well-established animal
Alzheimer’s disease models (Hsiao et al., 1996;
Oddo et al., 2003) which express the human APP695
with Swedish mutations (K670N-M671L), alone or in
combination with MAPT P301L and PSEN1 M146V, re-
spectively—were analysed because these Tg animals are
recognized to display progressive tau-dependent, hippo-
campus-based synaptic and cognitive impairments (Oddo
et al., 2006; Castillo-Carranza et al., 2015; Amar et al.,
2017). The hippocampal parenchyma was examined in
the present study, since this vulnerable cerebral area: (i)
selectively and disproportionally degenerates at early
stages of mild cognitive impairment prior to the clinical
diagnosis of full-blown dementia (Honer et al., 1992;
West et al., 1994; Gomez-Isla et al., 1996; Kordower
et al., 2001; Scheff et al., 2006a, b); (ii) preferentially
develops tau neuropathology into synaptic compartments,
whose initial deterioration is considered the best correlate
of cognitive decline in Alzheimer’s disease symptomatol-
ogy by critically subserving the transition from normal
aging to mild cognitive impairment (Braak and Braak,
1991, Arriagada et al., 1992; Guillozet et al., 2003;
Markesbery et al., 2006, 2010; Pooler et al., 2014;
Spires-Jones and Hyman, 2014).
Before addressing the possible benefits offered by
systemic delivery of the cleavage-specific 12A12mAb
(D-25NH2tau(Q26–36aa)-terminus), we determined an ap-
propriate lifetime at which Tg-Alzheimer’s disease mice
could be employed for antibody immunization experiments.
In light of these considerations, the in vivo level of the
pathogenic 20–22 kDa NH2htau was measured by western
blotting sodium dodecyl sulphate-polyacrylamide gel electro-
phoresis analyses carried out on synaptosomal preparations
from hippocampi of WT and Alzheimer’s disease Tg ani-
mals of both genetic backgrounds at three ages (1, 3, 6-
month-old Tg2576 and 3xTg). As shown in Fig. 1A and B,
the signal intensity of 12A12mAb-positive NH2htau immu-
noreactivity band was virtually undetectable in 6-month-old
cognitively intact controls but appeared to be up-regulated
in diseased animals (one-way ANOVA followed by
Dunnett’s post hoc test for multiple comparisons Tg2576
F(3,12) ¼ 13.34, P¼ 0.0004; 3-month-old Tg2576 versus
6-month-old WT, ***P< 0.0005; 6-month-old Tg2576 ver-
sus 6-month-old WT, **P< 0.01; 3xTg F(3,12) ¼ 76.79,
P< 0.0001; 1-month-old 3xTg versus 6-month-old WT,
*P< 0.05; 3-month-old 3xTg versus 6-month-old WT,
****P< 0.0001; 6-month-old 3xTg versus 6-month-old
WT, ****P< 0.0001). Consistent with previous investiga-
tions from rodent preparations (Rohn et al., 2002; Corsetti
et al., 2008) and human nerve terminals specimens
(Amadoro et al., 2010, 2012; Corsetti et al., 2015;
Sokolow et al., 2015), the steady-state expression level of
the neurotoxic 20–22 kDa NH2htau truncated fragment
significantly increased and time-dependently accumulated
starting from 1 month of age into synaptic-enriched frac-
tions of cognitively impaired older animals from both
Alzheimer’s disease Tg mouse models. The specific ability
of 12A12mAb in binding the 20–22 kDa NH2htau frag-
ment in vitro, both in recombinant and native forms, was
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Figure 1 The i.v.-injected 12A12mAb anti-tau antibody is biologically active into the animals’ hippocampus. (A, B) Western blot
analysis carried out on hippocampi from Tg2576 and 3xTg Alzheimer’s disease mice at different ages (1, 3 and 6 months old) and from 6-month-
old WT by probing with 12A12mAb (left). b-III tubulin was used as loading control. Arrows on the right side indicate the molecular weight (kDa)
of bands calculated from migration of standard proteins. Full uncropped blots are available in Supplementary Fig. 5. Pooled data and relative
densitometric quantifications are reported on the right. In this and all other figures, in box-and-whisker plots the centre lines denote median
values, edges are upper and lower quartiles, whiskers show minimum and maximum values and points are individual experiments. Statistically
significant differences (see details in the main text) were calculated by ANOVA followed by post hoc test for multiple comparisons among more
than two groups. P< 0.05 was accepted as statistically significant (*P < 0.05; **P < 0.01; ***P < 0.0005; ****P < 0.0001). (C) Western blotting
analysis was carried out by probing with anti-mouse IgG as primary antibody (Thermo-Fisher 10400C) on hippocampal protein extracts (40lg)
from animals of the three experimental groups (WT, ‘naı̈ve’ 3xTg, 3xTg þ mAb) which underwent i.v. injection with saline or 12A12mAb (see
details in Materials and methods section). b-III tubulin was used as loading control. Arrows on the right side indicate the molecular weight (kDa)
of bands calculated from migration of standard proteins. Full uncropped blots are available in Supplementary Fig. 5. Notice that 3xTg animals,
which are systemically i.v. injected for 14 days with 12A12mAb (see details in Materials and methods section), exhibit high levels of cerebral
mouse IgG when compared to not-vaccinated controls confirming that a fraction of mAb injected into the tail vein is present in the hippocampal
parenchyma. Asterisks point to the light and heavy antibody chains (25 and 50 kDa, respectively). (D) Brain levels of anti-tau antibody 12A12mAb
were evaluated by ELISA in the TBS-soluble fraction of hippocampal homogenates from WTand 3xTg mice that i.v. received saline or 12A12mAb
for 14 days (see details in the Materials and methods section). The ELISA used to measure the anti-tau antibody relies on the plate-immobilized
recombinant NH226-44aa tau which, being the minimal Alzheimer’s disease-relevant (Borreca et al., 2018) active moiety of the parental longer
NH226-230 (Amadoro et al., 2004, 2006), was used as catching peptide. Notice that a significant portion of the 12A12mAb in 3xTg brains is
bound to endogenous NH2htau and does non-specifically interact with the large amount of intracellular tau released during homogenization.
Statistically significant differences (see details in the main text) were calculated by ANOVA followed by post hoc test for multiple comparisons
among more than two groups. P < 0.05 was accepted as statistically significant.
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checked by western blotting and ELISA (Supplementary
Fig. 1).
Having ascertained that the NH2htau accumulated into
hippocampal synapses under pathological conditions in
association with progressive disruption of animals’ mem-
ory/learning function(s), we investigated whether the
12A12mAb could be exploited to systemic tau-directed
immunization regimen. In particular, we ascertained
whether 12A12mAb was able to gain access to the cere-
bral parenchyma after its peripheral administration, an
optimal prerequisite for local engagement of the patho-
genic target and its successful neutralization/clearance
in vivo. To this aim, 6-month-old mice from these two
different strains (Tg-Alzheimer’s disease) were infused
over 14 days with two weekly injections of 12A12mAb
(30 lg/dose) administered on two alternate days to the
lateral vein of the tail. Both age-matched WTs and
‘naı̈ve’ (i.e. not-immunized) Tg Alzheimer’s disease coun-
terparts, which were sham-infused under the same experi-
mental conditions with vehicle (saline) only, were also
included as negative controls. By probing with anti-mouse
IgG used as primary antibody, western blotting analysis
(Fig. 1C) carried out on hippocampal protein extracts
from the three experimental groups (WT, ‘naı̈ve’ Tg-
Alzheimer’s disease, Tg-Alzheimer’s disease þ mAb
which, importantly, were sacrificed and thoroughly per-
fused with PBS in order to make sure that their brains
were free of blood contaminations) showed that
12A12mAb-injected 3xTg animals exhibited high levels of
cerebral mouse IgG when compared to not-vaccinated,
saline-treated controls. This qualitative finding is in line
with previous reports on the ability of other, intravenous-
ly administered anti-tau antibodies to cross the blood–
brain barrier of diseased Tg mice (about 0.1% of
delivered total amount), likely owing to its age-related im-
pairment and increased permeability (Asuni et al., 2007;
Blair et al., 2015; Mably et al., 2015; Bennett et al., 2018).
Next, to confirm that peripherally delivered 12A12mAb
was actually able to bind the NH2htau in vivo, we car-
ried out ELISA quantitative test on TBS-soluble fractions
isolated from hippocampi of WT, ‘naı̈ve’3xTg and 3xTg
þ mAb animals after 14 days i.v. injection. Healthy, WT
mice infused with 12A12mAb under the same experimen-
tal conditions (WT þ mAb) were also included to ascer-
tain whether 12A12mAb could enter the brain from
periphery despite the intact blood–brain barrier and/or
the lack of tau pathology into the CNS. It’s worth under-
lying that: (i) the ELISA test aimed at assessing the cere-
bral amount of injected 12A12mAb is based on the
plate-immobilized synthetic NH226-44aa which, being the
minimal Alzheimer’s disease-relevant (Borreca et al.,
2018) active moiety of the parental longer NH226-230
(Amadoro et al., 2004, 2006), was used as catching pep-
tide; (ii) only the free (i.e. unoccupied) antibody can read-
ily bind to its immobilized specific antigen and be
measured, whereas the tau-bound antibody is not detect-
able. As shown in Fig. 1D, a sizeable proportion of the
injected 12A12mAb was unbound and biologically active
(antigen-binding competent) in 3xTg brains, being able to
recognize the synthetic plate-immobilized recombinant tau
peptide. Interestingly, the levels of i.v.-administered
12A12mAb were significantly lower in 3xTg þ mAb ex-
perimental group than in WT þ mAb counterpart (two-
way ANOVA analysis followed by Bonferroni’s post hoc
test for multiple comparisons, genotype  treatment
interaction F(1,24) ¼ 28.92, P< 0.0001; WT þ saline
versus Tg-Alzheimer’s disease þ saline n.s., P> 0.99;
****P< 0.0001 for all other pair comparisons), indicat-
ing that a higher fraction of this antibody is actually
bound in vivo to the endogenously generated NH2htau
antigen—and thus less available for capture in in vitro
ELISA assay—into the hippocampi from diseased animals
than in healthy controls. Similar results were also found
in 6-month-old Tg2576 animals from the other genetic
background which were analysed and treated under the
same experimental conditions (data not shown).
Collectively, these findings demonstrated that: (i) the
pathological tau truncated at its N-terminal domain early
accumulates into hippocampal synapses from Tg-
Alzheimer’s disease, suggesting that it might contribute to
the age-dependent disruption of animals’ memory and
learning functions; (ii) after its i.v. injection, 12A12mAb
can be actively up-taken into the brain because an appre-
ciable percentage of free and antigen-binding competent
form of antibody is present into the hippocampus both
from healthy controls and 3xTg immunized mice, regard-
less of the integrity of their blood–brain barrier and/or
the presence of tau pathology; (iii) 12A12mAb does not
aspecifically interact, neither in WT nor in 3xTg, with
the large amount of intracellular full-length normal tau
which is routinely released during procedure of samples
homogenization, in line with our previous in vivo obser-
vations advocating its cleavage-specificity towards the
NH2htau truncated fragment (Amadoro et al., 2012,
Supplementary Fig. 1); (iv) 12A12mAb is not in limiting
amount and, thus, endowed with potential therapeutic ef-
fect (in vivo target-engagement) because after immuniza-
tion it is locally detectable in its active/antigen-competent
state into mouse brains, with higher level in the WT con-
trols than in diseased 3xTg ones.
12A12mAb passive immunization
reduces both pathological tau and
APP/Ab metabolisms into synaptic
compartments from treated
Alzheimer’s disease Tg mice at the
prodromal stage of neuropathology
Co-occurrence between tau and Ab pathology has been
described to take place within neuronal processes and
nerve ending compartments at early stages of Alzheimer’s
disease (Takahashi et al., 2010; Amadoro et al., 2012;
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Spires-Jones and Hyman, 2014; Rajmohan and Reddy,
2017). In the preclinical models of Tg2576 and 3xTg, Ab
exerts its synaptotoxicity, at least in part, via tau, but
both separate and synergistic neurodegenerative mecha-
nisms have been also described in these two experimental
paradigms (Nisbet et al., 2015; Li and Gotz, 2017;
Polanco et al., 2018). Recent in vitro and in vivo evi-
dence have demonstrated that Ab and tau pathology—in
addition to their direct and/or indirect interaction
(Castillo-Carranza et al., 2015; Dai et al., 2017, 2018;
Rajamohamedsait et al., 2017)—can damage the synaptic
terminals in an APP-dependent manner suggesting that its
increased expression level per se should be considered as
an additional therapeutic target to preserve the integrity
and function of crucial neuronal networks (Gulisano
et al., 2018; Kametani and Hasegawa, 2018; Schreurs
et al., 2018).
In view of these considerations, we investigated whether
the antibody-mediated neutralization of pathogenic NH2-
truncated tau following i.v. 12A12mAb infusion could
mitigate in vivo the occurrence of neurochemical deriva-
tives from the abnormal APP and tau metabolisms which
are largely recognized to compromise the Alzheimer’s dis-
ease nerve terminals at prodromal disease stages (Braak
and Del Tredici, 2015). To this aim, western blotting so-
dium dodecyl sulphate-polyacrylamide gel electrophoresis
analyses (Fig. 2, Tg2576; Fig. 3, 3xTg) were carried out
on hippocampal synaptosomal preparations from the
three experimental groups (WT, ‘naı̈ve’ Tg-Alzheimer’s
disease, Tg-Alzheimer’s disease þ mAb) of both genetic
backgrounds (3-month-old Tg2576 and 3xTg) by probing
with both 12A12mAb and specific commercial antibodies
detecting the Alzheimer’s disease-like, site-specific tau
hyperphosphorylation at Ser202/Thr205 epitope (AT8)
(Goedert et al., 1995) and the accumulation of soluble
6E10-positive APP/Ab derivatives (Teich et al., 2015). As
shown in Figs 2A and 3A—and in line with Fig. 1A and
B—the intensity signal of the neurotoxic 20–22 kDa
NH2htau truncated fragment was markedly increased in
saline-treated, ‘naı̈ve’ Tg-Alzheimer’s disease mice when
compared to non-Tg WT controls (one-way ANOVA fol-
lowed by Bonferroni’s post hoc test for multiple compari-
sons F(2,18) ¼ 117.5, P< 0.0001, Tg2576; F(2,18) ¼
34.54, P< 0.0001, 3xTg; ****P< 0.0001, Tg2576 versus
WT; ****P< 0.0001, 3xTg versus WT). Importantly, the
12A12mAb treatment significantly reduced the synaptic
load of 20–22 kDa NH2htau form(s) in Tg-Alzheimer’s
disease animals from both strains indicating that this
antibody, after i.v. delivery, successfully engaged/inter-
cepted its target into hippocampus with consequent neu-
tralization/clearance in vivo (one-way ANOVA followed
by Bonferroni’s post hoc test ****P< 0.0001, Tg2576 þ
mAb versus Tg2576; ****P< 0.0001, 3xTg þ mAb ver-
sus 3xTg). Following 12A12mAb immunization, the AT8
immunoreactivity was strongly inhibited in Tg-
Alzheimer’s disease animals (one-way ANOVA followed
by Bonferroni’s post hoc test F(2,18) ¼ 23.72,
P< 0.0001, Tg2576; F(2,18) ¼ 42.18, P< 0.0001, 3xTg;
Tg2576 versus WT, ****P< 0.0001; Tg2576 þ mAb ver-
sus WT n.s., P¼ 0.7913; Tg2575 þ mAb versus Tg2576,
***P< 0.0005; 3xTg versus WT, ****P< 0.0001; 3xTg
þ mAb versus WT n.s., P¼ 0.3747; 3xTg þ mAb versus
3xTg, ****P< 0.0001), proving that the anti-truncated
tau antibody was able to down-regulate the extent of tau
neuropathology in vivo (Figs 2C and 3C). A drastic de-
cline and/or disappearance of the expression levels of
6E10-positive APP/Ab specie(s) (i.e. 4 kDa Ab monomer,
14 kDa low-molecular weight Ab oligomers or APP C-ter-
minal fragment (bCTF)) was also clearly observed in
Tg-Alzheimer’s disease hippocampal synapses from treated
experimental groups of both genetic backgrounds (Figs 2E
and 3E and F) (one-way ANOVA followed by
Bonferroni’s post hoc test F(2,18) ¼ 104.7, P< 0.0001,
Tg2576; F(2,18) ¼ 115.8, P< 0.0001, 3xTg; Tg2576 ver-
sus WT, ****P< 0.0001; Tg2576 þ mAb versus WT
n.s., P¼ 0.0536; Tg2576 þ mAb versus Tg2576,
****P< 0.0001; ****P< 0.0001 for all pair comparisons
from 3xTg). Importantly, the steady-state expression level
of total tau detected by probing with H150 and DC25
(Figs 2B and 3B), two commercial anti-pan tau antibodies
binding both murine and human tau isoforms (Zilka
et al., 2006; Lee et al., 2010; Um et al., 2011; Schroeder
et al., 2016), was unchanged in synapses from Alzheimer’s
disease Tg animals after 12A12mAb immunization regi-
men, with significantly higher level of total tau detected in
3xTg in comparison with WT controls due to the presence
of both endogenous and human Tg proteins (one-way
ANOVA followed by Bonferroni’s post hoc test F(2,18) ¼
0.3014, P¼ 0.7434 Tg2576; F(2,18) ¼ 22.8 P< 0.0001
3xTg; n.s. P> 0.999 for all pair comparisons from
Tg2576; 3xTg versus WT ***P< 0.0005; 3xTg þ mAb
versus WT ****P< 0.0001; 3xTg þ mAb versus 3xTg
n.s. P¼ 0.1577). These findings are consistent with tau
cleavage-specificity of 12A12mAb which selectively binds
in vivo the neurotoxic NH2htau truncated specie(s)
(Amadoro et al., 2012; Corsetti et al., 2015) without
showing any cross-reaction towards the full-length form of
protein (Supplementary Fig. 1). Finally, as visualized by
22C11 commercial antibody (Figs 2D and 3D),
12A12mAb immunization resulted to act upstream on Ab
production by normalizing the disease-associated up-regu-
lation in the expression level of APP full-length holopro-
tein in both Tg Alzheimer’s disease mice models (one-way
ANOVA followed by Bonferroni’s post hoc test F(2,18) ¼
46.07 P< 0.0001 Tg2576; F(2,18) ¼ 97.33 P< 0.0001
3xTg; Tg2576 versus WT ****P< 0.0001; Tg2576 þ
mAb versus Tg2576 ****P< 0.0001; Tg2576 þ mAb ver-
sus WT n.s. P¼ 0.999; ****P< 0.0001 3xTg for all com-
parisons). Interestingly, this evidence supports more recent
studies which suggest a prominent, causal role of APP ac-
cumulation in triggering synaptotoxicity and tauopathy
(Kametani and Hasegawa, 2018; Schreurs et al., 2018).
Collectively, these results demonstrate that: (i) when i.v.
administrated to young (3 months old) Tg2576 and 3xTg
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Figure 2 Reduction of the hippocampal NH2htau in Tg-Alzheimer’s disease (Tg2576) mice immunized with 12A12mAb
ameliorates the disease-associated synaptic neuropathology. Representative blots (n ¼ 5) of sodium dodecyl sulphate-polyacrylamide
gel electrophoresis western blotting analysis (left) on isolated synaptosomal preparations from hippocampal region of animals from three
experimental groups (WT, Tg-Alzheimer’s disease and Tg-Alzheimer’s disease þ mAb) of Tg2576 strain to assess the content of the NH2htau
fragment (A), total tau full-length (B), AT8-phosphorylated tau (C), APP holoprotein (D) and Ab monomeric and oligomeric species (E). Data
were quantified for molecular weight size ranges for each antibody and normalized to b-III tubulin which was used as loading control (F) and
relative densitometric quantifications are reported (right). Arrows on the right side indicate the molecular weight (kDa) of bands calculated from
migration of standard proteins. Full uncropped blots are available in Supplementary Fig. 6. Notice that changes in levels of total tau are not
statistically significant. Statistically significant differences (see details in the main text) were calculated by ANOVA followed by post hoc test for
multiple comparisons among more than two groups. P < 0.05 was accepted as statistically significant (*P < 0.05; **P < 0.01; ***P < 0.0005;
**** P < 0.0001).
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Figure 3 Reduction of the hippocampal NH2htau in Tg-Alzheimer’s disease mice (3xTg) immunized with 12A12mAb
ameliorates the disease-associated synaptic neuropathology. (A–G)Representative blots (n ¼ 5) of sodium dodecyl sulphate-
polyacrylamide gel electrophoresis western blotting analysis (left) on isolated synaptosomal preparations from hippocampal region of animals
from three experimental groups (WT, Tg-Alzheimer’s disease and Tg-Alzheimer’s disease þ mAb) of 3xTg strain to assess the content of the
NH2htau fragment (A), total tau full-length (B), AT8-phosphorylated tau (C), APP holoprotein (D) and Ab monomeric and oligomeric species
(E/F). Data were quantified for molecular weight size ranges for each antibody and normalized to b-III tubulin which was used as loading control
(G) and relative densitometric quantifications are reported (right). Arrows on the right side indicate the molecular weight (kDa) of bands
calculated from migration of standard proteins. Full uncropped blots are available in Supplementary Fig. 7. Notice that changes in levels of total
tau are not statistically significant. Statistically significant differences (see details in the main text) were calculated by ANOVA followed by post
hoc test for multiple comparisons among more than two groups. P < 0.05 was accepted as statistically significant (*P < 0.05; **P < 0.01; ***P <
0.0005; ****P < 0.0001).
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mice—two well-established Alzheimer’s disease animal
models showing tau-dependent neuropathology (Oddo
et al., 2006; Castillo-Carranza et al., 2015; Amar et al.,
2017)—the cleavage-specific 12A12mAb is able to reach
an appreciable concentration into the hippocampal paren-
chyma ensuing an effective binding/degradation of the
pathologic 20–22 kDa NH2htau form(s); (ii) the in vivo
antibody-mediated removal of the 20–22 kDa NH2htau
form(s) alleviates the detrimental alterations of both APP/
Ab and tau metabolisms (i.e. AT8 tau hyperphosphoryla-
tion, APP/Ab species accumulation and processing) com-
monly occurring at the earliest stage of Alzheimer’s
disease progression into nerve endings; (ii) the
12A12mAb-mediated immunodepletion of the toxic 20–
22 kDa NH2htau form(s) takes place in the absence of
any significant change in the stability/turnover of normal
full-length tau protein which is known to be endowed
with important physiological functions into synaptic com-
partments (Pooler et al., 2014; Regan et al., 2017) and
whose reduction, even if partial, is extremely harmful in
terminally differentiated post-mitotic neurons in vivo




Tg mice after i.v. 12A12mAb
delivery
Having established that classical molecular determinants
underlying the phenotypic Alzheimer’s disease manifesta-
tions are strongly reduced at early/pre-symptomatic stages
of neuropathology following peripheral administration of
12A12mAb, cognitive functioning of symptomatic Tg-
Alzheimer’s disease animals (6-month-old Tg2576 and
3xTg) was analysed under the same schedule of treatment
by means of a comprehensive behavioural test battery
(Fig. 4, Tg2576; Fig. 5, 3xTg).
The NOR task is a paradigm which is considered an
appropriate readout for measures of learning/memory im-
pairment in Tg and non-Tg animal models of tauopa-
thies, including Alzheimer’s disease (Polydoro et al. 2009;
Lanté et al., 2015). Relevantly, the NOR behavioural
task: (i) involves brain areas such as transentorhinal/ento-
rhinal/perirhinal cortices and hippocampus which are
pathologically relevant in this field, being affected by
neurofibrillary tau changes at early stages of disease
(Braak and Braak, 1991; Lasagna-Reeves et al., 2011,
2012; Bengoetxea et al., 2015; Sankaranarayanan et al.,
2015); (ii) is a non-aversive learning paradigm, avoiding
the potential confounds of using differential rewards or
punishments, able to evaluate the hippocampal-dependent
episodic memory (Antunes and Biala, 2012; Leger et al.,
2013) which is the first type of memory affected in
Alzheimer’s disease patients (Reed et al., 1997; Zola and
Squire, 2001; de Toledo-Morrell et al., 2007; Salmon and
Bondi, 2009; Grayson, et al., 2015). Owing to innate
and spontaneous preference of mice towards novelty, any
increase in exploration of the novel object (NO) during
the test session is to be ascribed to the animal’s ability in
discriminating it from the familiar one (FO). This param-
eter was quantified as preference index (PI), which is cal-
culated as the percentage of time spent exploring the new
object over the total time spent exploring the two objects.
In the recognition session, a PI for the NO >50% indi-
cated that the NO was preferred, <50% that the FO
was preferred and at 50% that no object was preferred
(Hammond et al., 2004).
Interestingly (Figs 4A and 5A), Tg2576 and 3xTg mice
receiving 12A12mAb showed a significant rescue in
short-term memory deficits when tested in this hippocam-
pal-dependent task, being able to distinguish NO from
FO (Tg2576 þ mAb PI¼ 58.6%; 3xTg þ mAb
PI¼ 66.41%) just as WT, healthy non-Tg mice (B6SJL
PI¼ 59.44%; C57 PI¼ 68.0%, respectively). On the other
hand, saline-treated/‘naı̈ve’ Tg-Alzheimer’s disease mice
from both strains exhibited a poor performance when
evaluated in NOR test because they spent the same time
in exploring the NO versus the FO (Tg2576
PI¼ 48.51%; 3xTg PI¼ 50.48%, respectively).
Accordingly, a two-way ANOVA of behavioural data
(treatment  object discrimination) indicated significant
difference between the three experimental groups of both
strains (F(1,32) ¼ 6.60 P¼ 0.01 for Tg2576; F(2,56) ¼
3.4 P¼ 0.04 for 3xTg) with the NO being preferred from
12A12mAb-infused Alzheimer’s disease Tg animals
(Fisher’s post hoc test NO versus FO Tg2576 þ mAb:
**P< 0.01; 3xTg þ mAb: ***P< 0.0005) which behaved
in the same manner of WT, non-Tg ones (Fisher’s post
hoc test NO versus FO B6SJL: ***P< 0.0005; C57:
***P< 0.0005). Conversely, not-immunized Alzheimer’s
disease mice from both genetic backgrounds did not dis-
criminate between NO and FO object and displayed de-
fective mnestic abilities without any preference for NO
(Fisher’s post hoc test Tg2576: P¼ 0.61; 3xTg: P¼ 0.32).
Furthermore, these results were not due to an intrinsic in-
ability of animals to interact with the objects because no
significant difference (treatment  object discrimination)
was measured during training phase among the animals’
cohorts from both strains which explored both objects
for the same length of time and without any particular
preference towards a side of the cage (two-way ANOVA
analysis F(2,32) ¼ 0.087 P¼ 0.916 for Tg2576 back-
ground; F(2,52) ¼ 1.09: P¼ 0.34 for 3xTg mice; Fisher’s
post hoc test left object versus right object B6SJL:
P¼ 0.53, Tg2576: P¼ 0.20, Tg2576 þ mAb: P¼ 0.30;
Fischer’s post hoc test left object versus right object C57:
P¼ 0.72, 3xTg: P¼ 0.91, 3xTg þ mAb: P¼ 0.11).
In addition to the objects’ recognition memory, the hip-
pocampal formation is devoted to store information
about places in the organism’s environment, their spatial
relations and the existence of specific objects in specific
places (spatial memory) (O’Keefe and Conway, 1978;
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Figure 4 Improved cognition in Tg-Alzheimer’s disease (Tg2576) mice immunized with 12A12mAb. (A–C) Fourteen days after
i.v. 12A12mAb immunization, the in vivo effect of NH2htau removal on cognitive performance was investigated in animals from the three
experimental groups (WT, Tg-Alzheimer’s disease and Tg-Alzheimer’s disease þ mAb) of Tg2576 genetic background in the NOR (A), OPR
(B) and Y-maze (C) tasks (top to bottom). For NOR (A) and OPR (B): right and left histograms, respectively, represent the PI (%) of
corresponding values measured during the test trial among animals from the different experimental groups (WT, Tg-Alzheimer’s disease and
Tg-Alzheimer’s disease þ mAb) of Tg2576 genetic background. The columns refer to objects presented during training and test trial. Analysis of
PI (%) measured as time spending in the exploration of the novel/DO/(time spending in the exploration of novel/DO þ time spending in the
exploration of familiar/SO)  100. Data were expressed as means 6 SEM (n ¼ 6–10). Values are means of at least three independent
experiments and statistically significant differences (see details in the main text) were calculated by ANOVA followed by post hoc test for multiple
comparisons among more than two groups. P < 0.05 was accepted as statistically significant (*P < 0.05; **P < 0.01; ***P < 0.0005; ****P <
0.0001). For Y-maze (C): right and left histograms, respectively, represent the total entries (the total arm entries correspond to the total number
of arms entered) and the spontaneous alternation (the number of alternations corresponds to the successive entries into three different arms in
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Broadbent et al., 2004; Manns and Eichenbaum, 2009).
Accordingly, immunized and not-immunized animals from
the three experimental groups run the object place recog-
nition task, another hippocampal-dependent paradigm
which examines the memory/learning ability of mice in
spatial relationships, rather than in objects recognition,
by calculating the time spent in discriminating the spatial-
ly displaced ‘old familiar’ object relative to the stationary
‘old familiar’ object (Antunes and Biala, 2012; Vogel-
Ciernia and Wood, 2014). Rodents normally display a
clear preference for the object moved to a novel place
[displaced object (DO)] in comparison to the object that
remains in the same (familiar) place [stationary object
(SO)], which confirms their proficiency for remembering
which spatial locations have or have not been engaged
earlier (Warburton et al., 2013).
Again (Figs 4B and 5B), cognitive impairment of mice
from the two genetic backgrounds (Tg2576 and 3xTg)
was relieved following i.v. 12A12mAb injection because
immunized animals were able to distinguish DO from SO
(Tg2576 PI¼ 73.26%; 3xTg PI¼ 69.07%) by performing
in spatial novelty memory task just as WT, healthy non-
Tg ones (B6SJL PI¼ 79.71%; C57 PI¼ 71.48%, respect-
ively). On the other hand, saline-treated ‘naı̈ve’
Alzheimer’s disease Tg mice showed no preference for the
moved object as they spent nearly equivalent amounts of
time exploring the DO and SO which confirms that these
not-immunized animals from both strains have object lo-
cation memory dysfunction (Tg2576 home-cage
PI¼ 48.29%; 3xTg home-cage PI¼ 52.53%, respectively).
Consistently, a two-way ANOVA of behavioural data
(treatment  object discrimination) indicated significant
difference between the three animals’ cohorts in both
strains analysed (F(2,20) ¼ 9.68 P¼ 0.001 for Tg2576;
F(2,50) ¼ 33.11 P< 0.001 for 3xTg) with the DO being
preferred from 12A12mAb-immunized Alzheimer’s disease
mice (Fisher’s post hoc test DO versus SO Tg2576 þ
mAb: *P< 0.05, 3xTg þ mAb: ***P< 0.0005) which
behaved in the same manner of WT, non-Tg ones
(Fisher’s post hoc test DO versus SO B6SJL:
***P< 0.0005, C57: ***P< 0.0005). In contrast, ‘naı̈ve’
Tg2576 and 3xTg mice displayed no difference between
DO and SO object with no obvious preference for DO
(Fisher’s post hoc test Tg2576: P¼ 0.76; 3xTg: P¼ 0.35).
Besides, regardless of the genetic background, no vari-
ation (treatment  object discrimination) was measured
during the training phase among the three experimental
groups which explored both objects for the same length
of time and without any particular preference towards a
side of the cage (two-way ANOVA analysis F(2,20) ¼
0.47 P¼ 0.63 for Tg2576 background; F(2,52) ¼ 0.79
P¼ 0.46 for 3xTg mice; Fisher’s post hoc test left object
versus right object B6SJL: P¼ 0.58, Tg2576: P¼ 0.76,
Tg2576 þ mAb: P¼ 0.47; Fischer’s post hoc test left ob-
ject versus right object C57: P¼ 0.24, 3xTg: P¼ 0.86,
3xTg þ mAb: P¼ 0.68).
After assessing the object discrimination and spatial
memory, we also tested mice in the spontaneous alterna-
tion by employing the Y-maze, an hippocampal-depend-
ent episodic-like behavioural test for measuring their
willingness to explore new environments (exploratory ten-
dency). Animals are started from the base of the Y-
shaped apparatus placed horizontally and allowed to free-
ly explore all three arms. The number of arm entries and
the number of triads are recorded in order to calculate
the percentage of alternation (Deacon and Rawlins, 2006;
Borchelt and Savonenko, 2008) which is based on the
fact that the rodent tends to choose the arm not visited
before, reflecting memory (spatial-based working mem-
ory) of the previous choice (Paul et al., 2009).
Interestingly (Fig. 4C), in line with previous literature
findings (King and Arendash, 2002; Deacon et al., 2008;
Yassine et al., 2013), the spontaneous alternation task
did not reliably detect cognitive deficits in Tg2576 mice
at 6 months of age because no difference was found in
their working-memory performance in comparison to cog-
nitively intact, WTs, both in spontaneous alternation and
total entries into the arms (spontaneous alternation one-
way ANOVA F(2,12) ¼ 0.15 P¼ 0.86; Fisher’s post hoc
test WT versus Tg2576 P¼ 0.99; Tg2576 versus Tg2576
þ mAb P¼ 0.68; Total Entries F(2,12) ¼ 0.28 P¼ 0.76;
Fisher’s post hoc test WT versus Tg2576 P¼ 0.81;
Tg2576 versus Tg2576 þ mAb P¼ 0.72). All three
groups of mice alternated between arms above chance
level (22.2%), indicating that neither cohort showed im-
pairment in this test. On the other hand (Fig. 5C) and in
line with previous reports (Spires-Jones and Knafo, 2012;
Ameen-Ali et al., 2017), although disability was clearly
discernible in naı̈ve, cognitively impaired 3xTg at 6
months of age when tested in comparison to age-matched
WTs (Spontaneous alternation one-way ANOVA F(2,28)
¼ 7.44 P¼ 0.025; Total entries F(2,28) ¼ 18.01
P¼ 0.00001), no significant improvement in their refer-
ence and working-memory/learning abilities was detected
Figure 4 Continued
overlapping triplet sets) of animals from the different experimental groups (WT, Tg-Alzheimer’s disease and Tg-Alzheimer’s disease þ mAb) of
Tg2576 genetic background. The percentage alternation was calculated as the ratio between number of correct triplets (e.g. ABC) and total
entrances minus 2, multiplied by 100. Values are means of at least three independent experiments and statistically significant differences (see
details in the main text) were calculated by ANOVA followed by post hoc test for multiple comparisons among more than two groups. P < 0.05
was accepted as statistically significant (*P < 0.05; **P < 0.01; ***P < 0.0005; ****P < 0.0001). FO ¼ familiar object; LO ¼ left object; OPR ¼
object place recognition; RO ¼ right object.
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Figure 5 Improved cognition in Tg-Alzheimer’s disease (3xTg) mice immunized with 12A12mAb. Fourteen days after i.v.
12A12mAb immunization, the in vivo effect of NH2htau removal on cognitive performance was investigated in animals from the three
experimental groups (WT, Tg-Alzheimer’s disease and Tg-Alzheimer’s disease þ mAb) of 3xTg genetic background in the NOR (A), OPR
(B) and Y-maze (C) tasks(top to bottom). For NOR (A) and OPR (B): right and left histograms, respectively, represent the PI (%) of
corresponding values measured during the test trial among animals from the different experimental groups (WT, Tg-Alzheimer’s disease and Tg-
Alzheimer’s disease þ mAb) of 3xTg genetic background. The columns refer to objects presented during training and test trial. Analysis of PI (%)
measured as time spending in the exploration of the novel/DO/(time spending in the exploration of novel/DO þ time spending in the
exploration of familiar/SO)  100. Data were expressed as mean 6 SEM (n ¼ 6–10). Values are means of at least three independent experiments
and statistically significant differences (see details in the main text) were calculated by ANOVA followed by post hoc test for multiple
comparisons among more than two groups. P < 0.05 was accepted as statistically significant (*P < 0.05; **P < 0.01; ***P < 0.0005;
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following systemic injection with 12A12mAb (Fisher’s
post hoc test analysis, Total entries: WT versus 3xTg
***P< 0.0005; WT versus 3xTg þ mAb ***P< 0.0005;
3xTg versus 3xTg þ mAb P¼ 0.19; Spontaneous alterna-
tion WT versus 3xTg ***P< 0.0005; WT versus 3xTg þ
mAb *P< 0.05; 3xTg versus 3xTg þ mAb P¼ 0.17). In
this framework, it is worth stressing that, in contrast to
3xTg characterized by genetically driven tau pathology,
Tg2576 mice express human APP (K670N/
M671L)PS1(M146V) transgene in endogenous back-
ground of murine not-mutated tau. Therefore, the dis-
crepancy in results between two different Tg Alzheimer’s
disease rodent models, each having its own characteris-
tics, may be due to the aggressive phenotype of the
human tau-overexpressing 3xTg strain, which is likely to
require a more optimized immunization regimen (anti-
body dosage, time of treatment, timing of administration)
in order to fully prevent and/or delay its robust cognition
symptomatology. Alternatively, the reversible nature of
in vivo tau neuropathology could be restricted within
strain-specific temporal window(s) because of the com-
plex and multifactorial feature of Alzheimer’s disease
pathology involving a wide range of inflammatory, oxida-
tive, neurodegenerative causative mechanisms (Webster
et al., 2014; Velazquez et al., 2018).
Finally, to rule out the possibility that the in vivo en-
hancement of cognitive skills in immunized animals
involved an effect of 12A12mAb treatment on body en-
ergy homeostasis known to influence their sensorial-
motor abilities, metabolic rate (EE) from vehicle- or anti-
body-infused non-Tg WT mice was assessed by means of
indirect calorimetry during 2 days of continuous analysis/
recording. As shown in Supplementary Fig. 2A, an un-
paired t-test of EE data revealed no significant difference
between the two experimental groups [vehicle-treated ani-
mals: (M¼ 25.29; SEM ¼ 60.61) or mAb-treated ani-
mals: (M¼ 24.92; SEM ¼ 60.64 t(142) ¼ 0.42)].
Furthermore, the EE analysis in resting conditions
(REE)—i.e. by considering only the EE values generated
in the absence of motor activity (i.e. 0–2 counts)—did
not show any variation in heat production from
12A12mAb-treated healthy WT mice, thus corroborating
the important finding that intra-caudal injection either
with vehicle alone (M¼ 18.51; SEM ¼ 60.43), or with
antibody (M¼ 18.08; SEM ¼ 60.52 t(142) ¼ 0.42), was
ineffective in altering the whole body REE, whatever the
physical motor activity involved (t(118) ¼ 0.63)
(Supplementary Fig. 2B).
In keeping with this finding, no change in recognition
memory performance was detected when vehicle- or
12A12mAb-treated WT mice were evaluated in the
NOR paradigm (Supplementary Fig. 2C and D), further
indicating that the immunization regimen per se did not
affect cognitive functions under non-pathological set-
tings. Two-way ANOVA of time (s) of exploration of
FO versus NO showed no significant difference for
treatment factor (F(1,12) ¼ 0.28 P ¼ ns), significant ob-
ject novelty factor (F(1,12) ¼ 18.74 P< 0.001) and no
significant effect of the interaction between treatment
and object novelty (F(1,12) ¼ 0.08 P ¼ ns). Post hoc
Tukey’s test for object novelty (FO versus NO) further
confirmed that both vehicle-treated (**P< 0.01) and
mAb-treated (**P< 0.01) WT animals exhibited intact
recognition memory (Supplementary Fig. 2C). No differ-
ence was found between the PI of vehicle-treated and
mAb-treated WT groups (unpaired sample t-test: vehicle-
treated and mAb-treated ones, t(6) ¼ 1.672, P ¼ ns,
Supplementary Fig. 2D), thus demonstrating that
12A12mAb-induced injection did not impair recognition
memory in non-Tg mice. In agreement with the cleav-
age-selectivity of antibody (Supplementary Fig. 1), the
12A12mAb treatment appeared to be avoid of potential
adverse side-effects in discriminatory skills when injected
in healthy animals, notwithstanding its ability of pene-
trating the animals’ blood–brain barrier and/or success-
fully accessing to hippocampus in biologically active
state (Fig. 1D).
Likewise, no difference in cognitive performance was
detected when sham-immunized 6-month-old Tg2576
mice (i.e., animals administered with IgG isotype control,
at the same dosage and period of time) were tested for
performance in NOR paradigm in comparison with their
vehicle-treated counterparts. Two-way ANOVA analysis
on time (s) of exploration of FO versus NO displayed no
significant difference for object factor (F(1,8) ¼ 0.66 P ¼
ns) and treatment factor (F(1,8) ¼ 0.67 P ¼ ns) in ve-
hicle- and IgG-treated Tg mice (Supplementary Fig. 3A).
Moreover, the unpaired sample t-test of PI data showed
that neither vehicle nor IgG administration improved the
deficit of recognition memory (compare Supplementary
Figure 5 Continued
****P < 0.0001). For Y-maze (C): right and left histograms, respectively, represent the total entries (the total arm entries correspond to the total
number of arms entered) and the spontaneous alternation (the number of alternations corresponds to the successive entries into three different
arms in overlapping triplet sets) of animals from the different experimental groups (WT, Tg-Alzheimer’s disease and Tg-Alzheimer’s disease þ
mAb) of 3xTg genetic background. The percentage alternation was calculated as the ratio between number of correct triplets (e.g. ABC) and
total entrances minus 2, multiplied by 100. Values are means of at least three independent experiments and statistically significant differences
(see details in the main text) were calculated by ANOVA followed by post hoc test for multiple comparisons among more than two groups. P <
0.05 was accepted as statistically significant (*P < 0.05; **P < 0.01; ***P < 0.0005; ****P < 0.0001). FO ¼ familiar object; LO ¼ left object; OPR
¼ object place recognition; RO ¼ right object.
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Fig. 3B with Supplementary Fig.2C), thus confirming the
lack of ability of Tg animals in discriminating between
FO and NO (t(4) ¼ 0.05, P ¼ ns). Similar results were
detected following IgG infusion in 6-month-old 3xTg
mice when compared to not-immunized Tg counterparts
(data not shown).
Active behaviour, such as exploring a novel environ-
ment, induces the expression of the immediate-early
gene Arc (activity-regulated cytoskeletal-associated pro-
tein, or Arc/Arg3.1) in several brain regions, including
the hippocampus. Activity-regulated cytoskeleton-associ-
ated protein messenger RNA is quickly induced and dy-
namically up-regulated by behavioural experience and
the protein is selectively translated into activated den-
drites, being required for the memory consolidation of
an early initial potentiation of synaptic transmission into
a lasting form of long-term potentiation (LTP) (Ramirez-
Amaya et al., 2005, 2013; Plath et al., 2006; Korb and
Finkbeiner, 2011). Interestingly and consistent with their
cognitive enhancement in behavioural assessments (Figs
4 and 5), western blotting analyses performed on hippo-
campal synaptosomal-enriched preparations isolated
from post-trained animals (Supplementary Fig. 4A and
B) showed that the stimulus-driven, steady-state expres-
sion level of activity-regulated cytoskeleton-associated
protein was significantly up-regulated in 12A12mAb-
immunized Tg2576 and 3xTg mice when compared to
their saline-treated cognitively impaired counterparts
(one-way ANOVA followed by Bonferroni’s post hoc
test F(2,18) ¼ 34.81 P< 0.0001 Tg2576; F(2,18) ¼
33.32 P< 0.0001 3xTg; Tg2576 þ mAb versus Tg2576
****P< 0.0001; Tg2576 þ mAb versus WT n.s.
P¼ 0.1441; 3xTg þ mAb versus 3xTg ***P< 0.0005;
3xTg þ mAb versus WT **P< 0.01). Conversely and in
line with their scarce performance in novelty-based cog-
nitive tasks (Figs 4 and 5), naı̈ve Alzheimer’s disease Tg
animals—which were not systemically infused with
12A12mAb—displayed marked defects in the experience-
dependent induction of activity-regulated cytoskeleton-
associated protein expression, and then in their proc-
esses of memory/learning trace consolidation following
its initial acquisition, as shown by the finding that
immunoreactivity signal of protein in their synaptic frac-
tions was significantly lower than that from healthy WT
controls (one-way ANOVA followed by Bonferroni’s
post hoc test ****P< 0.0001 for Tg2576 versus WT
and for 3xTg versus WT).
Collectively, these experiments indicate that passive
immunization with 12A12mAb, which selectively targets
the neurotoxic NH2htau fragment(s) in vivo, significant-
ly improves cognition in symptomatic (6 months old)
Tg-Alzheimer’s disease animals by rescuing their instinct-
ual and innate preference for novelty (object recognition
and object location skills) when tested in two patho-
logically relevant, hippocampal-dependent behavioural
tasks.
Loss in dendritic spine density is




Dendritic spines, the sites of excitatory synapses protruding
from dendritic shafts, are cellular morphological specializa-
tions devoted to memory-forming processes in neurons
(Segal, 2005). Being extremely dynamic structures, modifica-
tion in their number, size and/or shape is an important
index of synaptic plasticity occurring in response to external
environmental inputs (Pignataro et al., 2015). As a conse-
quence, loss of dendritic arbourization (length/complexity)
in vulnerable neuronal networks, although occurring along
different spatio-temporal patterns among commonly used
Tg animal models, undoubtedly represents one of the ear-
liest changes of structural plasticity which critically contrib-
utes over time to the disruption of neuronal network with
consequent appearance of cognitive dysfunction in
Alzheimer’s disease and other related dementias (Knobloch
and Mansuy, 2008; Spires-Jones and Knafo, 2012; Cochran
et al., 2014; Dorostkar et al., 2015). Therefore, in order to
complement our behavioural findings, we assessed the
neuroanatomical effect of passive immunization with
12A12mAb on dendritic connectivity from 6-month-old
Alzheimer’s disease animals. To this aim, hippocampal sec-
tions from mice of the three experimental groups were
stained by Golgi-Cox impregnation procedure followed by
quantitative assessment of dendritic spine density (number
of spines per unit length) along both apical and basal com-
partments of individual CA1 pyramidal neurons (Fig. 6).
As shown in Fig. 6A and in line with previous works
reporting in Tg2576 an early decline of dendritic boutons
which undergo dystrophy and shrinkage (Lanz et al.,
2003; Jacobsen et al., 2006; D’Amelio et al., 2011), the
spine loss was detectable at the age of 6 months in apical
compartments of CA1 hippocampal neurons from this
genetic background when animals were compared to non-
Tg controls. Importantly, in 12A12mAb-immunized
Alzheimer’s disease group the apical spine density was
significantly ameliorated up to the level of saline-injected
cognitively intact WTs (one-way ANOVA followed by
Fisher’s post hoc test F(2,8) ¼ 10.828, P ¼ 0.00530;
**P< 0.01 WT versus Tg2576; **P< 0.01 Tg2576 þ
mAb versus Tg2576), indicating that treatment was
strongly effective in blocking/preventing the dendritic de-
generation. Interestingly, no difference was detected when
spines were counted in the basal compartment of CA1
neurons from the three experimental cohorts (one-way
ANOVA F(2,8) ¼ 0.71926, P¼ 0.51611), suggesting that
age-related spine changes in Tg2576 mice initially involve
the apical dendritic arbours with no apparent effect on
basal dendrites of CA1 pyramidal neurons which are
more likely to be affected only later, when their
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structural plasticity and stability (formation and elimin-
ation) is completely impaired (Spires-Jones et al., 2007).
On the other hand and in stark contrast with previous
literature findings (BIttner et al., 2010), we found out
(Fig. 6B) that the reduction in the spines density, both in
apical and basal compartments of individual CA1 pyram-
idal neurons, already started from the age of 6 months in
cognitively impaired 3xTg mice (one-way ANOVA fol-
lowed by Fisher’s post hoc test apical: F(2,7) ¼ 18.697,
P¼ 0.00156; basal: F(2,7) ¼ 13.404, P¼ 0.00404) which
exhibited lower values in dendritic protrusions counts
when compared with their age-matched, non-Tg WTs.
Remarkably, degeneration of dendritic spine structures was
robustly decreased in immunized 3xTg mice (apical:
**P< 0.01 3xTg þ mAb versus 3xTg; **P< 0.01 WT
versus 3xTg; basal: **P< 0.01 3xTg þ mAb versus 3xTg;
*P< 0.05 WT versus 3xTg) pointing out that—possibly as
result of increased afferent inputs to the CA1 from other
neighbouring hippocampal areas and/or as a local positive
effect in the CA1 region—12A12mAb treatment was able
to mitigate the age-related pathology of post-synaptic con-
nections from symptomatic 6-month-old 3xTg mice, both
in their apical and basal compartments.
Systemic administration of





In order to investigate whether 12A12mAb immunization,
in addition to its protective actions on Alzheimer’s
Figure 6 Immunization with 12A12mAb in Tg-Alzheimer’s disease mice is protective against the dendritic spines density loss
which affects the memory and learning processes. (A, B) Comparative photomicrographs of Golgi-stained hippocampal CA1 neurons
showing dendritic segments from animals from three experimental groups (WT, Tg-Alzheimer’s disease and Tg-Alzheimer’s disease þ mAb) of
both strains (Tg2576, 3xTg) (left, refers to CA1 pyramidal neurons dendrites scale bar: 5 mm). Box-and-whisker plots (right) depict the
morphometric analysis of the dendritic spine density from the three experimental groups. Values are expressed as number of spines per 1 mm
segment. Statistically significant differences (comparisons were made on single mouse values obtained by averaging the number of spines counted
on neurons of the same mouse) were calculated by ANOVA followed by post hoc test for multiple comparison among more than two groups. P
< 0.05 was accepted as statistically significant (*P < 0.05; **P < 0.01; ***P < 0.0005; ****P < 0.0001).
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disease-related behavioural and neurochemical and neuro-
anatomical abnormalities, was also able to exert an effect
on electrophysiological correlate(s) of the memory/learn-
ing processes, hippocampal synaptic transmission and
plasticity in the Schaffer collateral pathway were com-
pared between Tg and WT animals from both genetic
backgrounds (Fig. 7A–D for Tg2576; Fig. 7E–H for
3xTg).
We first recorded basal synaptic transmission and the
strength of pre-synaptic Schaffer collaterals activation (i.e.
axonal depolarization) from CA3-to-CA1 synapses in
acute brain slices from 6-month-old WT and age-matched
Tg2576 animals treated with saline vehicle or
12A12mAb, respectively. To this aim, we first generated
input/output curves by measuring the field excitatory
post-synaptic potentials elicited in the stratum radiatum
of the CA1 area after stimulation of the Schaffer collater-
als at increasing intensities. As shown in Fig. 7A and B
and in line with previous investigations reporting no
change in basal synaptic transmission in this Tg
Alzheimer’s disease model at 6 months of age (Chapman
et al., 1999; Nobili et al., 2017), the input/output curves
displayed a similar trend among the three experimental
groups (two-way repeated-measures ANOVA for stimulus
intensity  experimental group followed by Bonferroni’s
post hoc test F(12,282) ¼ 0.8409 P¼ 0.6082; n.s.
P> 0.05 for all comparisons).
Next, we investigated the pre-synaptic function by
assessing paired-pulse facilitation, a short-term plasticity
paradigm which inversely depends on Ca2þ-dependent
pre-synaptic changes in neurotransmitter release probabil-
ity at nerve endings (Manabe et al., 1993; Debanne
et al., 1996; Dobrunz and Stevens, 1997; Dobrunz et al.,
1997; Thomson, 2000; Zucker and Regehr, 2002). Again
(Fig. 7C), short-term potentiation was almost identical
among the three animals’ cohorts (two-way repeated-
measures ANOVA for paired-pulse interval  experimen-
tal group, followed by Bonferroni’s post hoc test
F(10,170) ¼ 0.51 P¼ 0.8839; n.s. P> 0.05 for all com-
parisons), consistent with previous results referring no
significant dissimilarity in paired-pulse facilitation be-
tween 6-month-old Tg2576 and WT littermates (Jung
et al., 2011; Nobili et al., 2017).
In contrast to the basic synaptic transmission (input–
output relationship and paired-pulse facilitation), the
‘classical’ N-methyl-D-aspartate (NMDA) receptor-depend-
ent LTP paradigm at Schaffer collaterals/CA1 synapses—
a long-lasting enhancement of the strength/efficacy of ex-
citatory synaptic transmission which is widely used in
investigations on numerous APP/Ab models of
Alzheimer’s disease (Rowan et al., 2003; Shankar et al.,
2008)—turned out to be significantly compromised in 6-
month-old Tg2576 mice in comparison to age-matched
WTs (Fig. 7D). Following the induction of LTP by deliv-
ery of trains of high-frequency stimulation at half-max-
imal intensity, field excitatory post-synaptic potential
slopes appeared to decay down to baseline in 6-month-
old Tg2576 animals so that no persistent, activity-driven
potentiation was measurable starting from 30 min after
induction which was indicative of an impaired function
of hippocampal Schaffer collaterals/CA1 synapses.
Importantly and in keeping with improvement of cogni-
tive performance in hippocampal-dependent behavioural
assessments, peripheral administration of 12A12mAb was
able to mitigate in vivo the disease-related LTP deficiency
of symptomatic Tg2576 animals, as shown by the fact
that the LTP amplitude calculated after application of
high-frequency stimulation was significantly increased in
immunized experimental group when compared to ‘naı̈ve’
cognitively impaired counterpart (one-way ANOVA fol-
lowed by Bonferroni’s post hoc test F(2,21) ¼ 19.38
P< 0.0001; ***P< 0.0005 Tg2576 versus WT; *P< 0.05
Tg2576 þ mAb versus Tg2576; Tg2576 þ mAb versus
WT **P< 0.01). Moreover, these electrophysiological
investigations further corroborated the finding that the
disruption of synaptic plasticity in hippocampal Schaffer
collateral commissural pathway from this Alzheimer’s dis-
ease model was more likely due to altered post-synaptic
signalling pathways, given that no alteration in paired-
pulse facilitation was contextually detected in Tg animals
at 6 months of age (Chapman et al., 1999; Jacobsen
et al., 2006; Jung et al., 2011; Nobili et al., 2017).
In contrast with results from symptomatic Tg2576
mice, in 3xTg paradigm the input/output relationship
revealed a significant reduction of field excitatory post-
synaptic potential slopes evoked by increasing stimulation
intensities (Fig. 7E and F) when 6-month-old Tg animals
were compared to WT counterparts (two-way repeated-
measures ANOVA for stimulus intensity  experimental
group followed by Bonferroni’s post hoc test F(12,204) ¼
5.812 P< 0.0001; *P< 0.05 and **P< 0.01 WT versus
3xTg for paired comparisons). Most importantly, cumula-
tive distributions of field excitatory post-synaptic poten-
tial slopes within the range of 100 and 300 lA of
stimulus amplitude were shifted to higher values in
12A12mAb-immunized Alzheimer’s disease group in con-
trast to ‘naı̈ve’, cognitively impaired counterpart, indicat-
ing that antibody treatment positively influenced the fast
glutamatergic transmission in this genetic background
(#P< 0.05, ##P< 0.01, ###P< 0.001 for 3xTg versus 3xTg
þ mAb for paired comparisons with Bonferroni’s post
hoc test). No change in paired-pulse facilitation short-
term plasticity (Fig. 7G) was found among the three
experimental cohorts (two-way ANOVA paired-pulse
interval  genotype followed by Bonferroni’s post hoc
test F(12,198) ¼ 0.3464 P¼ 0.9792 n.s. P> 0.05 for all
comparisons), consistent with previous data showing that
the abnormalities in pre-synaptic release machinery were
not discernible between 6-month-old 3xTg and age-
matched WTs when measured in a facilitation electro-
physiological paradigm (Oddo et al., 2003). In a way
similar to Tg2576, hippocampal slices from 6-month-old
12A12mAb-injected 3xTg animals displayed a strong po-
tentiation after high-frequency stimulation bout, pointing
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Figure 7 Reduction of cognitive deficits in 12A12mAb-immunized Tg-Alzheimer’s disease mice correlates with an increased
LTP. (A, D) For Tg2576; (E, H) for 3xTg) time plot of average fEPSP responses (A, E) and changes in magnitude of LTP at CA3-Ca1 synapses
(D, H) were calculated among animals (n ¼ 6–10) from three experimental groups (WT, Tg-Alzheimer’s disease and Tg-Alzheimer’s disease þ
mAb) of both strains. At least seven slices from six different mice were recorded for each experimental condition. Data are presented as the
mean (6SEM). The traces above the plot show fEPSPs at baseline (1) and at 60 min after LTP induction (2). The box-whisker plots show pooled
data. Statistically significant differences (see details in the main text) were calculated by ANOVA followed by post hoc test for multiple
comparisons among more than two groups. P < 0.05 was accepted as statistically significant (*P < 0.05; **P < 0.01; ***P < 0.0005;
(continued)










attolica del Sacro C
uore user on 02 Septem
ber 2020
to a strong protective action evoked in vivo by the anti-
body treatment on the cellular/molecular correlate(s) of
their memory/learning processes (one-way ANOVA fol-
lowed by Bonferroni’s post hoc test F(2,33) ¼ 7.018
P¼ 0.0029; **P< 0.01 3xTg versus WT; *P< 0.05 3xTg
þ mAb versus 3xTg; 3xTg þ mAb versus WT n.s.
P> 0.05). Notably, when LTP was calculated in 6-
month-old 3xTg mice (Fig. 7H), a lower post-tetanic po-
tentiation was found against WTs suggesting that, in this
Alzheimer’s disease strain, the LTP reduction in magni-
tude and persistence was more likely due to deficits of in-
duction (either pre- and/or post-synaptic), in line with
structural and functional modifications observed both in
their basal synaptic transmission and dendritic spine
density (Fig. 6B).
Taken together, these electrophysiological recordings in-
dicate that disruption of excitatory synaptic transmission
and plasticity detected at 6 months of age in hippocampal
CA3-CA1 circuit of these two genetically distinct Tg-
Alzheimer’s disease animal models, although manifests at
different rate and involves non-overlapping causative
mechanism(s), was significantly rescued following in vivo
peripheral administration of 12A12mAb.
Expression levels of inflammatory
astroglial and microglial markers
are also down-regulated in
6-month-old 12A12mAb-immunized
Tg-Alzheimer’s disease animals
The inflammatory response—which is one of the earliest
manifestations of neurodegenerative tauopathies, including
Alzheimer’s disease (Bellucci et al., 2004; Yoshiyama et al.,
2007; Wes et al., 2014; Leyns et al., 2017; Ishikawa et al.,
2018)—may act as a double-edged sword being either det-
rimental or protective depending on the context
(Schlachetzki and Hull, 2009). On the one hand, activated
glial cells contribute to the Alzheimer’s disease pathogenesis
by means of diverse mechanisms including complement-
mediated synapse removal, non-cell autonomous spreading
of pathological seeds/conformers, extracellular release of in-
flammatory mediators such as pro-inflammatory cytokines,
complement components, chemokines, free radicals and
gliotransmitters which, in turn, trigger neurodegeneration.
On the other hand, astro- and microglial reactions are
endowed with beneficial role in Alzheimer’s disease envir-
onment by stimulating the digestion/clearance of pathogen-
ic Ab and tau species and, then, by preventing their
accumulation into insoluble cerebral lesions, the senile pla-
ques and neurofibrillary tangles.
To get further insights into protective effect evoked by
i.v. 12A12mAb-based immunization in Tg-Alzheimer’s
disease mice, the extent of inflammatory response was
assessed on hippocampi from 6-month-old Tg2576 and
3xTg mice of the three experimental groups (WT, ‘naı̈ve’
Tg-Alzheimer’s disease, Tg-Alzheimer’s disease þ mAb).
Western blotting analysis (Fig. 8) were carried out on
animals’ total extracts by probing with antibodies which
detect the glial fibrillary acidic protein and Iba1, whose
cell type-specific steady-state expression levels are recog-
nized as indicative of active astrogliosis and microgliosis,
respectively (Sydow et al., 2016). As shown in Fig. 8A
and B and regardless of the different genetic background,
the immunoreactivity signals of these two classical inflam-
matory markers were strongly increased in saline-treated,
‘naı̈ve’ Tg-Alzheimer’s disease mice in comparison to WT
controls, in line with previous findings reporting a prom-
inent astrocytic and microglial activation in hippocampal
parenchyma from these animal models (Olabarria et al.,
2010, 2011; Vogels et al., 2019). Remarkably, the gliosis
detected in 12A12mAb-injected Tg-Alzheimer’s disease
mice turned out to be significantly down-regulated com-
pared to their naı̈ve counterparts (one-way ANOVA fol-
lowed by Bonferroni’s post hoc test glial fibrillary acidic
protein: F(2,21) ¼ 169.4 P< 0.0001 Tg2576
****P< 0.0001 for all comparisons; F(2,18) ¼ 53.88
P< 0.0001 3xTg; ****P< 0.0001 3xTg versus WT;
****P< 0.0001 3xTg þ mAb versus 3xTg; n.s. P> 0.05
3xTg þ mAb versus WT; Iba1: F(2,21) ¼ 38.43
P< 0.0001 Tg2576 ****P< 0.0001 Tg2576 versus WT;
****P< 0.0001 Tg2576 þ mAb versus Tg2576; n.s.
P> 0.05 Tg2576 þ mAb versus WT; F(2,18) ¼ 273
P< 0.0001 3xTg ****P< 0.0001 for all comparisons),
indicating that: (i) the neuron-derived, extracellularly
released 20–22 kDa NH2htau form(s) is more likely to
be endowed with non-cell autonomous action by contri-
buting to the glial cells activation; (ii) the neuroprotective
effect of 12A12mAb appears to be, at least in part, due
to its modulatory role at the glia-neurons interplay.
Figure 7 Continued
**** P < 0.0001). (B, C) For Tg2576; (F, G) for 3xTg) input/output curves show the fEPSP slopes plotted against the corresponding stimulus
intensities recorded from hippocampal slices of animals (n ¼ 6–10) from three experimental groups (WT, Tg-Alzheimer’s disease and Tg-
Alzheimer’s disease þ mAb) of both strains (B, F). Comparison of PPF in animals (n ¼ 6–10) from three experimental groups (WT, Tg-
Alzheimer’s disease and Tg-Alzheimer’s disease þ mAb) of both strains (Tg2576, 3xTg) was also determined (C, G). PPF was induced by pairs of
stimuli delivered at increasing interpulse intervals (20, 50, 100, 200, 300, 500 ms). Data are presented as the mean (6SEM) facilitation ratio of
the second response relative to the first response. Statistically significant differences (see details in the main text) were calculated by ANOVA
followed by post hoc test for multiple comparisons among more than two groups. P < 0.05 was accepted as statistically significant (*P < 0.05; **P
< 0.01; ***P < 0.0005; ****P < 0.0001). fEPSP ¼ field excitatory post-synaptic potential; PPF ¼ paired-pulse facilitation.
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Taken together these findings indicate that sub-chronic
i.v. delivery of 12A12mAb into the hippocampus is de-
void of potentially adverse inflammatory effects associ-
ated to classical immunization regimen by limiting the
local activation of neuroglia which is per se both a con-
sequence to the disease process and a contributor to the
synaptic pathology and neuronal damage (Block et al.,
2007; Yoshiyama et al., 2007; Edison et al., 2008; Perry
et al., 2010; Schwab et al., 2010; Zotova et al., 2010).
Discussion
Accumulating evidence have suggested that the detrimen-
tal effects of Ab are dependent on tau pathology
(Rapoport et al., 2002; King et al., 2006; Roberson
et al., 2007; Ittner et al., 2010; Vossel et al., 2010;
Desikan et al., 2011; Shipton et al., 2011; Nussbaum
et al., 2012; Bloom, 2014) and that tau, rather than Ab
(Murray et al., 2015), serves a prominent role in early
synaptic decline and cognitive impairment (Arriagada
et al., 1992; Ashe and Zahs, 2010; Nelson et al., 2012;
Pontecorvo et al., 2017; Busche et al., 2019).
Independently of its ability of seeding aggregation, abnor-
mal extracellular/intracellular tau is per se neurotoxic
(Diaz-Hernandez et al., 2010; Medina and Avila, 2014a,
b; Hu et al., 2018) and propagates trans-synaptically
along interconnected neuronal networks in a stereotypical
manner which strongly correlates with the development
of clinical symptoms during Alzheimer’s disease
Figure 8 Inflammatory response (activation of astrocytes and microglia) is strongly down-regulated in 12A12mAb-
immunized Tg-Alzheimer’s disease mice. (A, B) Neuroinflammation processes (activation of astrocytes and microglia) were assessed on
hippocampal extracts from animals from three experimental groups (WT, Tg-Alzheimer’s disease and Tg-Alzheimer’s disease þ mAb) of both
strains (Tg2576, 3xTg) by western blotting analysis (left) for inflammatory proteins (glial fibrillary acidic protein, Iba1). Relative densitometric
quantification of intensity signals (right) indicates lower levels of glial fibrillary acidic protein and Iba1 in Tg-Alzheimer’s disease mice þ mAb
compared to not-immunized Tg-Alzheimer’s disease. GAPDH housekeeping expression serves as loading control. Arrows on the right side
indicate the molecular weight (kDa) of bands calculated from migration of standard proteins. Full uncropped blots are available in Supplementary
Fig. 8. Values are from at least three independent experiments and statistically significant differences (see details in the main text) were calculated
by ANOVA followed by post hoc test for multiple comparisons among more than two groups. P < 0.05 was accepted as statistically significant
(*P < 0.05; **P < 0.01; ***P < 0.0005; ****P < 0.0001). GAPDH ¼ glyceraldehyde-3-phosphate dehydrogenase; GFAP ¼ glial fibrillary acidic
protein.
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progression (Mohamed et al., 2013; Pooler et al., 2013;
Yamada et al., 2017). These pathologically relevant find-
ings represent the rationale which advocates the employ-
ment of tau-based strategies (Li and Gotz, 2017;
Congdon and Sigurdsson, 2018) as promising disease-
modifying intervention of slow progressing Alzheimer’s
disease and other human dementias (Novak et al., 2018a;
Jadhav et al., 2019), especially in view of the disappoint-
ing outcomes from Ab-targeting pharmacological and im-
munological approaches (Sigurdsson, 2008; Giacobini and
Gold, 2013; Doody et al., 2014; Salloway et al., 2014;
Schroeder et al., 2016; Agadjanyan et al., 2017). In this
connection, tau-directed passive immunotherapy—which
relies on the specific, epitope-directed antibody-mediated
depletion/clearance of its toxic species (Sigurdsson, 2008;
Pedersen and Sigurdsson, 2015; Li and Gotz, 2017;
Congdon and Sigurdsson, 2018)—has been recently rec-
ognized as a feasible, valuable approach to reduce the
neuropathology and to improve the memory/learning abil-
ities of experimental animal models of tauopathies
(Boutajangout et al., 2011; Chai et al., 2011; d’Abramo
et al., 2013; Yanamandra et al., 2013, 2015; Castillo-
Carranza et al., 2014; Dai et al., 2015, 2018;
Subramanian et al., 2017). However, several reasons
have hindered the clinical success of tau-targeting
approaches which are currently under investigation
(Giacobini and Gold, 2013; Novak et al., 2018a; Elmaleh
et al., 2019). To this regard, recent reports of ongoing
trials indicate that the potential flaws include: (i) study
design with the medical care given too late when neuron-
al damage is already present in a considerable extent so
that drugs/modulators are unable to compensate ad-
equately for the detrimental effects; (ii) systemic toxicity
owing to long-term and multiple administrations of
drugs/modulators used at high doses which can interfere
with the neuronal physiology (i.e. affect the normal
cellular metabolism and/or impact on the immune surveil-
lance); (iii) inadequate brain bioavailability of medica-
ments against the target substrate and/or the biochemical
pathway, even after crossing the blood–brain barrier; (iv)
adverse risks of inflammatory response, such as cerebral
microhaemorrhages (Elmaleh et al., 2019).
Here, we show that systemic administration with
12A12mAb—which selectively recognizes the human tau
at D25(DRKD26QGGYTMHQDQEGDTDAGLK44), a
known N-terminal truncation protein site (Quinn et al.,
2018) previously identified both in cellular and animal
Alzheimer’s disease paradigms (Corsetti et al., 2008) and
in human Alzheimer’s disease brains (Rohn et al., 2002;
Amadoro et al., 2012; Corsetti et al., 2015)—rescues the
neurochemical, anatomical, behavioural and electro-
physiological alterations underlying the Alzheimer’s dis-
ease phenotype in two well-established Tg mouse strains,
such as preclinical Tg2576 and 3xTg models. Of particu-
lar relevance is the fact that the Tg Tg2576 mice express-
ing human mutant APP (K670N/M671L), in contrast to
3xTg harbouring PS1(M146V), APP(Swe) and tau(P301L)
transgenes, display an endogenous genetic background of
murine not-mutated tau. Furthermore, since treatments
started when synaptic deterioration is evident but exten-
sive neurodegeneration has not yet developed turn out to
be the most effective in preventing the disease-associated
brain atrophy and related cognitive impairment (Bokde
et al., 2009; Elmaleh et al., 2019), our experimental eval-
uations are carried out on symptomatic animals which
are employed at early-middle stages (6 months old) of
pathology progression, when their hippocampi are not
largely compromised with massive neuronal loss. It is
also worth underlining that the 12A12mAb we employed
in the present study is specific for the pathological trun-
cated tau because it selectively binds in vivo the neuro-
toxic Alzheimer’s disease-linked NH226-230 fragment (i.e.
NH2htau) without showing any significant cross-reaction
towards the intact, physiological form of protein, in line
with our previous investigations (Amadoro et al., 2012).
To this point, biochemical and functional outcomes
in vivo measures further confirm that 12A12mAb: (i)
does not specifically interact with the abundant intracellu-
lar pool of endogenous normal full-length tau protein
whose steady-state level is unchanged in hippocampus
after its i.v. delivery in Tg-Alzheimer’s disease mice re-
gardless of the genetic backgrounds; (ii) is harmless when
injected in healthy, cognitive-intact WT mice, despite the
ability of successfully penetrating/reaching the brain in its
biologically active (antigen-competent) state under physio-
logical settings. Remarkably, the cleavage-specific
12A12mAb—which selectively binds 20–22 kDa
NH2htau without unproductive and deleterious cross-re-
action towards the physiological intact tau—appears to
be potent tool by providing measurable changes on
Alzheimer’s disease brain physiopathology which result in
significant improvement of the synaptic and cognitive def-
icits in affected animals, even after its short-term
(14 days) i.v. delivery. Conversely, there is proof that the
use of other therapeutic anti-tau antibodies binding all
forms of tau is more likely to result in considerable re-
duction of its effective dose available in vivo against the
target toxic tau species with consequent requirement of
more aggressive and prolonged applications (Novak
et al., 2018a). Furthermore, our results may have import-
ant clinical implications by prospecting the non-invasive
i.v. delivery route of 12A12mAb as effective and safe dis-
ease-modifying approach in contrasting the earliest neuro-
pathological and cognitive alterations of subjects which
suffer the chronically developing human Alzheimer’s dis-
ease and non-Alzheimer’s disease tauopathies character-
ized by an increased burden of tau truncation. In post-
mitotic neurons, tau is endowed with important functions
beyond the control of microtubule integrity and dynamics
(Sotiropoulos et al., 2017) and the treatment with tau-
targeting antibodies may have undesirable adverse side-
effects due to ‘loss of function’ of full-length protein
(Rosenmann et al., 2006; Rozenstein-Tsalkovich et al.,
2013; Bakota et al., 2017). Although we cannot rule out
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the later development of gliosis following prolonged im-
munization regimen, from a translational perspective an-
other interesting finding of the present study is that the
sub-chronic i.v. treatment with 12A12mAb is sufficient
per se to drive a robust therapeutic effect in the absence
of increased microglia and astrocyte activation which, on
the contrary, appears to be critical for the mechanism of
action of at least a few Ab-directed antibodies (Bard
et al., 2000; Wilcock et al., 2004) leading as byproduct
to excessive deleterious stimulation of local inflammatory
response (Lemere, 2013; Wisniewski and Goni, 2015).
We find no obvious evidence of neuroinflammatory re-
sponse which is known to cause mortality in WT mice
when actively immunized with various fragments of tau
(Rosenmann et al., 2006; Rozenstein-Tsalkovich et al.,
2013). Furthermore, the evidence that passive immuniza-
tion with 12A12mAb can normalize in vivo the APP/Ab
dysmetabolism in two independent genetic backgrounds
overexpressing human mutated APP (K670N/M671L) not
only unveils a novel and potential connection between
tau and APP/Ab, whereby toxic tau can upstream affect
APP/Ab pathology in damaging synapses, but also—and
more importantly—highlights the 20–22 kDa NH2-ter-
minal tau fragment as crucial target for Alzheimer’s dis-
ease therapy starting from its earliest stages which are
characterized by initial disruption of synaptic functions in
the absence of frank neuronal loss. Therefore, this study
prospects the peripheral administration of the humanized
counterpart of murine 12A12mAb as a novel, promising
multi-targeted intervention in preventing disease-associ-
ated cognitive deterioration in human beings suffering
Alzheimer’s disease-related dementias, being endowed
with higher clinical potentialities than those altering ei-
ther neuropathology alone (Oddo et al., 2006;
Rosenmann et al., 2006; Lambracht-Washington and
Rosenberg, 2013; Bakota et al., 2017).
Concerning the mechanism(s) of action involved in the
beneficial power of 12A12mAb immunization, in the pre-
sent study, we are unable to anticipate whether tau-
directed therapeutic effects offered by i.v. delivery of
12A12mAb involve only the extracellular or both intra-
cellular and extracellular pool of toxic truncated tau be-
cause we did not collect and analyse the level of
NH2htau fragment in CSF or interstitial fluid and
plasma. It is worth noting that the N-terminal, but not
C-terminal, fragments of tau including the 20–22 kDa
NH2htau form(s), are mainly secreted from synaptosomes
of Alzheimer’s disease brains (Sokolow et al., 2015) and
detected both in CSF from Alzheimer’s disease patients
(Johnson et al., 1997; Portelius et al., 2008; Meredith
et al., 2013; Amadoro et al., 2014; Chen et al., 2019;
Cicognola et al., 2019) and in conditioned media from
patient-derived induced pluripotent stem cells cortical
neurons (Bright et al., 2015; Kanmert et al., 2015; Sato
et al., 2018). The NH226-44 amino acidic stretch, which
is the minimal biological active moiety of parental 20–22
kDa NH2-truncated tau form(s) (Amadoro et al., 2010,
2012; Corsetti et al., 2015) has been recently recognized
as one among the potentially targetable tau epitopes for
promising Alzheimer’s disease immunotherapeutic inter-
ventions, being largely represented into CSF samples
(Barthélemy et al., 2016a, b; Sato et al., 2018) and in
autoptic specimens from affected subjects (Borreca et al.,
2018). Interestingly, previous in vitro, ex vivo and
in vivo experiments from our research group have dem-
onstrated that this short peptide when extracellularly
administered to hippocampal neurons dynamically per-
turbs the plasma membranes—mainly of distal axonal
compartments (Perini et al., 2019)—by exerting a dele-
terious action on synaptic connectivity and plasticity
being more likely internalized only after prolonged incu-
bation times (Florenzano et al., 2017; Borreca et al.,
2018). Moreover, studies have shown that tau antibodies
can be readily taken up by neurons, promote the intracel-
lular sequestration/clearance of pathological species by
means of different mechanisms and prevent their release
into the extracellular space followed by consequent
spreading throughout the brain (Asuni et al., 2007;
Krishnamurthy et al., 2011; Congdon et al., 2013; Gu
et al., 2013; Collin et al., 2014; Pedersen and Sigurdsson,
2015; Shamir et al., 2016). After its i.v. administration in
both healthy and disease mice, the 12A12mAb in circula-
tion seems to be able to successfully penetrate the hippo-
campus and engage in vivo its target at a sufficient level
to exert biologically relevant neuroprotective effects. The
N-terminal region of tau, despite the lack of the micro-
tubule binding domains which abnormally aggregate to
form paired helical filaments, is able to undergo higher
order of oligomerization (Feinstein et al., 2016) and, in
this framework, the binding of 12A12mAb to the
NH2htau may also prevent the trans-synaptic propagation
of detrimental insoluble tau. Therefore, both extracellular
and intracellular interaction between 12A12mAb and the
NH2htau might be plausible routes by which immuniza-
tion directed against this harmful, Alzheimer’s disease-
relevant N-truncated tau specie(s) operates in vivo.
Furthermore, although the immune system has been in-
creasingly recognized as an important player in the
immunotherapeutic approaches (Congdon and Sigurdsson,
2018; Katsinelos et al., 2019), the finding that the cogni-
tive skills improvement of 12A12mAb-injected
Alzheimer’s disease Tg mice are paralleled by a strong
and concomitant reduction of the disease-associated cere-
bral level of reactive gliosis further supports recent results
showing that (i) antibody-mediated targeting of patho-
logical tau in vivo does not necessarily required engage-
ment of microglia that may per se induce deleterious
neuroinflammation (Lee et al., 2016); (ii) the neuroprotec-
tive mechanism action evoked by tau-based immunother-
apy is more likely to rely on the direct neutralization of
toxic extracellular species and/or on preventing their up-
take by neurons (Congdon et al., 2013; Gu et al., 2013).
In this regard, glial activation and neuroinflammation
have been reported to severely impact on tau pathology
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directly, by participating to tau aggregation and degrad-
ation and spreading (Asai et al., 2015; Yuan et al., 2016;
Bolos et al., 2017; Hopp et al., 2018), or indirectly,
through a non-cell autonomous effect on neuronal signal-
ling via cytokine and complement factor and gliotransmit-
ter secretion (Liddelow et al., 2017; Piacentini et al.,
2017; Litvinchuk et al., 2018) and up-regulation of senes-
cence-associated genes (Bussian et al., 2018) and synapses
pruning (Marttinen et al., 2018; Vogels et al., 2019).
Another challenging question is whether the neuropro-
tection offered by 12A12mAb can be further ameliorated
in vivo following its prolonged administration, especially
in more severe 3xTg animal model, or sustained even
after its discontinuing immunization. Further investiga-
tions will be needed to better clarify the dose-dependent
effect of 12A12mAb treatment on pathology and cogni-
tive performance of Alzheimer’s disease Tg mice and how
long the beneficial effect can last beyond the period of
the immunization.
It is also worth stressing that—although mouse and
human tau amino acidic sequences are similar—there are
14 amino acid differences in the N-terminal region
(Andorfer et al., 2003; Bright et al., 2015; Hernandez
et al., 2019). Nevertheless, the extreme N-terminal se-
quence of tau protein starting at D25 encompasses a not-
canonical caspase(s) cleavage-site sequence (McStay et al.,
2008; Kumar et al., 2014) which has been identified both
in cellular (human SY5Y and rat PC12) and animal
(Alzheimer’s disease11 mice) Alzheimer’s disease models
(Rohn et al., 2002; Corsetti et al., 2008) and in human
Alzheimer’s disease brains (Rohn et al., 2002; Amadoro
et al., 2012; Quinn et al., 2018). Moreover results from
in vitro experiments and Tg animal models have shown
that truncation plays a causative role in remodelling the
highly flexible conformational ensemble of intrinsically
disordered protein tau into Alzheimer’s disease-like patho-
logical conformations (Novak et al., 2018b).
Conformational changes involving the amino-terminus of
tau early occur in Alzheimer’s disease and other related
tauopathies (Garcia-Sierra et al., 2003). Consistently,
Mukrasch et al., have demonstrated that—although the
largest part of tau441 amino acid sequence is devoid of
any ordered structure—the N-terminal 50 residues of pro-
tein favour a compact conformation, as indicated by
strong contacts within the residue stretch 1–20 and from
this region to residues 30–50 (Mukrasch et al., 2009).
Therefore it is reasonable to hypothesize that, although
the amino acid sequence of human and murine tau sur-
rounding this epitope is divergent, 12A12mAb is more
likely to recognize the newly generated, sequence- and
structural-based immunoreactive determinants whose for-
mation requires pathological truncation occurring under
Alzheimer’s disease conditions at D25 residue both in
human and rodent tau (Rohn et al., 2002; Corsetti et al.,
2008; Quinn et al., 2018; Amadoro et al., 2019). In sup-
port of this finding and in line with the experimental evi-
dence that temporary secondary structures occur in
causal relation with tau neuropathology progression, both
in isolated domains of the full-length protein and of
some of its fragments (Mukrasch et al., 2009; Avila
et al., 2016b; Fichou et al., 2019), by means of molecu-
lar dynamics (MD) simulations and SAXS experiments,
we have recently demonstrated that the short sequence
including the 26–44 of N-terminal region of human
tau—but not its reverse counterpart (tau44-26 peptide)—
undergoes isolated b-bridges, a-helices and 3-helix which
involve the Y29, T30, Q33, D34, Q35, E36 amino acid
residues (Perini et al., 2019). Importantly, these amino
acid residues are present both in murine and primate tau
sequence. Besides, the fact that 12A12mAb does not
change the expression level of full-length tau but select-
ively reduces the endogenously produced 20–22 kDa tau
fragment in both Alzheimer’s disease strains, as we
showed in western blotting Figs 2 and 3, further
strengthens the notion that a local conformational elem-
ent (i.e. sequence- and structure-based immunoreactive
epitope) is more likely to underlie its in vivo specificity in
targeting the neo-epitope of the N-derived truncated
pathological tau specie(s), both in human and mouse.
Finally, since the epitopes cannot be predicted reliably
from antigen primary amino acid sequences because some
novel epitopes can arise exclusively due to the alteration
of the molecule’s conformation (Opuni et al., 2018), fur-
ther experiments of immunoprecipitation followed by
mass spectrometry and alanine epitope scanning mapping
are needed to identify the crucial binding residues and
the precise structure of N-terminal of tau protein that are
directly involved in the interaction with 12A12mAb.
Concerning the interplay occurring in vivo between
APP/Ab and tau pathologies, according to the classical
Ab cascade hypothesis aberrant changes of tau metabol-
ism are considered downstream of Ab pathology which
acts as initial trigger (Hardy and Selkoe, 2002; De
Strooper and Karran, 2016). Consistently, compelling
studies have demonstrated that Ab can potentiate tau
abnormalities (Gotz et al., 2001; Lewis et al., 2001;
Oddo et al., 2004; Bolmont et al., 2007) and that an
enhanced neuropathology occurs following in vivo inter-
action between Ab and tau (Gotz et al., 2001; Lewis
et al., 2001; Hurtado et al., 2010; Bennett et al., 2017;
Pontecorvo et al., 2017; He et al., 2018; Jacobs et al.,
2018; Quiroz et al., 2018). In this regard, our findings
highlighting a novel mechanistic interplay between APP/
Ab and tau at synapses fit more well with other studies
showing that changes in tau metabolism precede Ab
pathology in aged and Alzheimer’s disease brains (Braak
and Del Tredici, 2004; Schonheit et al., 2004; Braak
et al., 2013; Jack et al., 2013) and that the removal of
pathogenetic species of tau can prevent in vivo the dele-
terious effect of both Ab and tau (Oddo et al., 2006;
Castillo-Carranza et al., 2015; Dai et al., 2017, 2018;
Rajamohamedsait et al., 2017). Remarkably, the spread-
ing/propagation of tau neuropathology into the Ab pla-
que-bearing cerebral cortex is associated with the
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transition from the preclinical (asymptomatic) to the clin-
ical (symptomatic) stage of Alzheimer’s disease
(Delacourte et al., 1999; Wang et al., 2016; Pontecorvo
et al., 2017). Furthermore, although the tau pathology to
evolve to full-blown Alzheimer’s disease requires the con-
comitant presence of Ab pathology (Braak and Del
Tredici, 2011; Duyckaerts, 2011; Jack et al., 2013; Crary
et al., 2014), the failure of anti-Ab therapies in prevent-
ing the disease progression suggests that Alzheimer’s dis-
ease pathogenesis might be driven by tau independently
of Ab (Giacobini and Gold, 2013). However, whether Ab
is necessary for tau neurotoxicity or whether the reverse
is true is still an open question (Ashe and Zahs, 2010).
On the other hand, recent data also suggest that tau and
Ab may be independent processes and reciprocally inter-
act over the evolution of Alzheimer’s disease (Small and
Duff, 2008; Mondragón-Rodrı́guez et al., 2010). In this
context, co-occurrence between tau and Ab within neur-
onal processes and synaptic compartments has been
described in Alzheimer’s disease (Hoover et al., 2010;
Ittner et al., 2010; Zempel et al., 2010; Amadoro et al.,
2012; Miller et al., 2014) and synaptic abnormalities
occur in aging Tg2576 and 3xTg mice (Spires-Jones
et al., 2007; Nisticò et al., 2012; Ameen-Ali et al., 2017).
Ab and tau pathologies exert synergistic effects on neur-
onal morphology/function (Rhein et al., 2009) particular-
ly at synapses (Hoover et al., 2010; Ittner et al., 2010;
Takahashi et al., 2010; Amadoro et al., 2012) believed to
initiate Alzheimer’s disease progression (Selkoe, 2002),
indicating that passive immunization with 12A12mAb
can contribute to improve disease-associated mnestic dis-
abilities at its early phases by preventing both pathogno-
monic toxic proteins from damaging synaptic connectivity
in pathologically relevant vulnerable neuronal circuits.
Furthermore, a recent hypothesis also suggests that syn-
aptic dysfunction in Alzheimer’s disease is triggered by
impairment of APP metabolism which further progresses
via tau pathology (Gulisano et al., 2018; Kametani and
Hasegawa, 2018; Schreurs et al., 2018). Consistently, an
increased level of APP and/or its C-terminal fragments
are able to induce axonal and synaptic defects (Rusu
et al., 2007; Rodrigues et al., 2012; Deyts et al., 2016;
Xu et al., 2016) associated with mis-localization of tau
(Blurton-Jones and Laferla, 2006; Hochgrafe et al.,
2013). Overexpression of APP promotes per se the seeded
aggregation of intracellular tau in cultured cell, suggesting
that APP, rather than Ab, can work as a receptor of ab-
normal tau fibrils (Takahashi et al., 2015) by accelerating
in vivo internalization in neurons (Holmes et al., 2013;
Mirbaha et al., 2015) followed by pathological accumula-
tion and propagation. Besides, both soluble/prefibrillar
extracellular toxic Ab and tau can damage the synaptic
terminals in APP-dependent manner (Puzzo et al., 2017;
Wang et al., 2017), suggesting a translation potential of
12A12mAb for APP-targeted therapy in patients.
Concerning the routes by which the 12A12mAb-medi-
ated removal of the NH2htau can affect the cross-talk
between Ab and tau neuropathology or interfere up-
stream with APP metabolism and/or its processing
in vivo, both cell- and non-cell autonomous action mech-
anisms (Alasmari et al., 2018) should be taken into ac-
count by operating in alternative but not mutually
exclusive manners and by acting at different transcrip-
tional (Bright et al., 2015; Zhang et al., 2018), transla-
tion (Asuni et al., 2014; Borreca et al., 2016; Meier
et al., 2016; Koren et al., 2019) and post-translational
(Amadoro et al., 2012) levels. Furthermore, variations in
the type of mechanism(s) engaged in vivo by 12A12mAb
in two APP mouse models analysed and/or dissimilarity
in their temporal progression of plaque deposition
(Ameen-Ali et al., 2017) are more likely to account for
the difference in the magnitude of antibody effect(s) on
APP/Ab mis-processing. At the present, in vitro, ex vivo
and in vivo experiments are being performed by our re-
search group to better clarify this important issue.
In conclusion, the present investigation not only high-
lights a novel dynamic positive feed-forward regulation
between APP/Ab and N-truncated tau in vivo by reinforc-
ing the concept of pathological tau as main therapeutic
target of Alzheimer’s disease but also hopefully helps to
design more efficacious and safety tau-directed interven-
tions by prospecting the 12A12mAb as beneficial and dis-
ease-modifying approach for the cure of Alzheimer’s
disease and other tauopathies.
Supplementary material
Supplementary material is available at Brain
Communications online.
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Avila J, Jiménez JS, Sayas CL, Bolós M, Zabala JC, Rivas G, et al. Tau
structures. Front Aging Neurosci 2016b; 8: 262.
Bakota L, Ussif A, Jeserich G, Brandt R. Systemic and network func-
tions of the microtubule-associated protein tau: Implications for tau-
based therapies. Mol Cell Neurosci 2017; 84: 132–41.
Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, et al.
Peripherally administered antibodies against amyloid beta-peptide
enter the central nervous system and reduce pathology in a mouse
model of Alzheimer disease. Nat Med 2000; 6: 916–9.
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Hernández F, Cuadros R, Ollá I, Garcı́a C, Ferrer I, Perry G, et al.
Differences in structure and function between human and murine
tau. Biochim Biophys Acta Mol Basis Dis 2019; 1865: 2024–30.
Hiramatsu M, Sasaki M, Nabeshima T, Kameyama T. Effects of
dynorphin A (1-13) on carbon monoxide-induced delayed amnesia
in mice. Pharmacol Biochem Behav 1997; 56: 73–9.
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